ClinicalTrials.gg
CompletedNCT02120352Updated Jun 12, 2024Results posted

A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects

A Phase 2 interventional study of CAB Oral Tablets and CAB LA in Infection, Human Immunodeficiency Virus and HIV Infections, sponsored by ViiV Healthcare. Completed at 50 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-12.

Primary conditionHIV InfectionsRegistry: InfectionsReclassifiedWhy we changed it
Registry
Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
HIV Infections
Why
  1. The study's listed conditions name HIV Infections, a narrower term within Infections.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
309
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 36 studies testing cabotegravir in HIV Infections — 4 open to participants now, 13 under way, 8 of them phase 3. cabotegravir · HIV Infections.

Enrollment
13th of 36
309 · median 200
Started
2014
the only one that year
Phase 2
8 of 36
none open now
Registered
5th of 36
by date
Lead sponsor
24 of 36
ViiV Healthcare

Among the 36 studies testing cabotegravir in HIV Infections, this one is the 13th largest by enrollment, is the only one that started in 2014, is one of 8 in phase 2, and was the 5th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.

Browse HIV Infections studies →

Open to participants now

4 of the 36 studies testing cabotegravir in HIV Infections are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About cabotegravir

cabotegravir: first FDA approval 2021 (VOCABRIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing cabotegravir in HIV Infections, or all of them as a file.
02

Study summary

This study is a Phase IIb, randomized, multicentre, parallel group, open-label, study having an overall objective to evaluate the antiviral activity, tolerability, and safety of two intramuscular (IM) dosing regimens of GSK744 LA plus TMC278 LA, relative to GSK744 30 milligram (mg) plus Abacavir/Lamivudine (ABC/3TC) given orally once daily (QD), in HIV-1 infected antiretroviral-naïve subjects. GSK744 is the oral formulation of GSK1265744 (cabotegravir), GSK744 LA is the long acting injectable formulation of GSK1265744 and TMC278 LA is the long acting injectable formulation of TMC278.

The study will consist of three parts: an Induction Period, Maintenance Period and Extension Period. There is also a Long-Term Follow Up Period for subjects who withdraw from the study and have received at least one dose of GSK744 LA and / or TMC278 LA. In the Induction Period, eligible subjects will receive a combination of an oral regimen of 30 mg of GSK744 and 600/300 mg of ABC/3TC, once daily for 20 weeks. In the Maintenance Period, eligible subjects will be randomized 2:2:1 at Day 1 to receive an IM regimen of GSK744 LA 400 mg + TMC278 LA 600 mg every 4 weeks for 96 weeks (Q4W), an IM regimen of GSK744 LA 600 mg + TMC278 LA 900 mg every 8 weeks for 96 weeks (Q8W), or to continue on the oral Induction Period regimen of GSK744 30 mg + ABC/3TC once daily for 96 weeks (or 104 weeks if continuing on to the Extension Period). The Extension Period will allow for a collection of longer term efficacy and safety and tolerability data from subjects receiving GSK744 LA and TMC278 LA.

The study will involve sufficient subjects at screening in order to ensure a total of approximately 265 subjects at the beginning of the Induction Period and approximately 225 subjects randomized into the Maintenance Period.

03

Conditions studied

  • Infection, Human Immunodeficiency Virus
  • HIV Infections

Browse trials for

Keywords

  • bi-monthly
  • GSK744
  • injectable
  • long acting
  • maintenance
  • abacavir
  • every other month
  • rilpivirine
  • HIV-1 infection
  • integrase inhibitor
  • TMC278 LA
  • RPV
  • non-nucleoside reverse transcriptase inhibitor
  • LA
  • once monthly
  • GSK1265744
  • induction
  • treatment satisfication
  • once daily
  • lamivudine
  • adherence
  • TMC278
  • therapy-naive
04

In context

HIV Infections Reclassified

4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.

This study's enrollment of 309 is above the median of 80 across 3,491 interventional studies indexed under HIV Infections.

Browse HIV Infections studies →

Lead sponsor

ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.

Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.

Compared within HIV Infections, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects screened for this study must be -1 infected and >=18 years of age.
  • A female subject is eligible to enter and participate in the study if she: is of non- defined as either (12 months of spontaneous amenorrhea and >=45 years of age) or physically incapable of becoming pregnant with documented tubal ligation, hysterectomy or bilateral oophorectomy or; is of child-bearing potential with a negative pregnancy test at both Screening and first day of the Induction Period and agrees to use one of the following methods of to avoid pregnancy 2 weeks prior to administration of IP, throughout the study, and for at least 2 weeks after discontinuation of all oral study medications and for at least 52 weeks after discontinuation of GSK744 LA and TMC278 LA: Complete abstinence from intercourse (where this is the subject's preferred and usual lifestyle); double barrier method (male condom/spermicide, male condom/diaphragm, diaphragm/spermicide); approved hormonal contraception; any intrauterine device (IUD) with published data showing that the expected failure rate is \<1% per year; male partner sterilization prior to the female subject's entry into the study, and this male is the sole partner for that subject; any other method with published data showing that the lowest expected failure rate is \<1% per year; any contraception method must be used consistently and in accordance with the approved product label. All subjects participating in the study must follow safer sexual practices including the use of effective barrier methods (e.g. male condom/spermicide) to minimize risk of HIV transmission.
  • HIV-1 infection as documented by Screening plasma HIV-1 RNA>=1000 c/mL.
  • >=200 cells/mm\^3 (or higher as local guidelines dictate).
  • ART-naive defined as having no more than 10 days of prior therapy with any antiretroviral agent following a diagnosis of HIV-1 infection. Any previous exposure to an HIV integrase inhibitor or non-nucleoside reverse transcriptase inhibitor will be exclusionary.
  • French subjects: In France, a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category.

Exclusion criteria

Exclusion Criteria:

  • Women who are breastfeeding.
  • Any evidence at screening of an active Center for Disease and Prevention Control (CDC) Category C disease, except cutaneous Kaposi's sarcoma not requiring systemic therapy.
  • Subjects with known moderate to severe hepatic impairment.
  • Any pre-existing physical or mental condition (including substance abuse disorder) which, in the opinion of the Investigator, may interfere with the subject's ability to comply with the dosing schedule and/or protocol evaluations or which may compromise the safety of the subject.
  • Subject who, in the investigator's judgment, poses a significant suicide risk. Recent history of suicidal behavior and/or suicidal ideation may be considered as evidence of serious suicide risk.
  • The subject has a tattoo or other dermatological condition overlying the gluteus region which may interfere with interpretation of injection site reactions.
  • History of ongoing or hepatitis within the previous 6 months, including chronic virus (HBV) infection (HBsAg positive). Asymptomatic individuals with chronic virus (HCV) infection will not be excluded, however Investigators must carefully assess if therapy specific for HCV infection is required; subjects who are anticipated to require such therapy during the randomized portion of the study must be excluded.
  • History of liver cirrhosis with or without hepatitis viral co-infection.
  • Ongoing or clinically relevant pancreatitis.
  • History of the following cardiac diseases: myocardial infarction, congestive heart failure, documented hypertrophic cardiomyopathy, sustained ventricular tachycardia.
  • Personal or known family history of prolonged syndrome.
  • Any condition which, in the opinion of the Investigator, may interfere with the absorption, distribution, metabolism or excretion of the drug or render the subject unable to receive study medication.
  • History or presence of allergy or intolerance to the study drugs or their components or drugs of their class. In addition, if heparin is used during PK sampling, subjects with a history of sensitivity to heparin or heparin-induced thrombocytopenia must not be enrolled.
  • Current or anticipated need for chronic anti-coagulation.
  • Any evidence of primary resistance based on the presence of any major resistance-associated mutation in the Screening result or, if known, any historical resistance test result.
  • Any verified Grade 4 laboratory abnormality.
  • Any acute laboratory abnormality at Screening, which, in the opinion of the Investigator, would preclude the subject's participation in the study of an compound.
  • Subject has estimated \<50 mL/min via Cockcroft-Gault method.
  • (ALT) >=5 times (ULN). Subjects with ALT >2xULN but \<5xULN may participate in the study, if in the opinion of the Investigator and GlaxoSmithKline (GSK) medical monitor the lab abnormality will not interfere with the study procedures or compromise subject safety.
  • Alanine aminotransferase (ALT) >=3xULN and >=1.5xULN (with >35% direct bilirubin).
  • Any clinically significant finding on screening or Baseline electrocardiograph (), specifically: Heart rate \<45 and >100 beats per minute (bpm) (Males) and \<50 and >100 bpm (Females) (100 to 110 bpm can be rechecked within 30 minutes to verify eligibility), QRS duration >120 milliseconds (msec), QTc interval (B or F) >450 msec; non-sustained (>=3 consecutive beats) or sustained ventricular tachycardia; sinus pauses >2.5 seconds; 2nd degree (Type II) or higher atrio-ventricular (AV) block; evidence of WPW (Wolff- Parkinson-White) syndrome (ventricular pre-excitation); pathologic Q waves defined as Q wave >40msec OR depth >0.4 mV; any significant arrhythmia (either on ECG or by history) which, in the opinion of the Investigator and GSK medical monitor, will interfere with the safety for the individual subject.
  • Subjects who are human leukocyte antigen (HLA)-B*5701 positive and unable to use an alternative nucleoside reverse transcriptase inhibitor (NRTI) backbone (subjects who are HLA-B*5701 positive may be enrolled if they use an alternative NRTI backbone that does not contain abacavir).
  • Exposure to an experimental drug and/or experimental vaccine within 28 days or 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent, whichever is longer, prior to the first dose of IP.
  • Treatment with any of the following agents within 28 days of Screening; radiation therapy, cytotoxic chemotherapeutic agents, tuberculosis therapy and Immunomodulators that alter immune responses (such as systemic , interleukins, or interferons)
  • Treatment with an -1 immunotherapeutic vaccine within 90 days of Screening.
  • Treatment with any agent, except recognized ART as allowed above, with documented activity against HIV-1 within 28 days of the first dose of IP.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
309 participants (actual)

Study arms

  • Experimental
    CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period)

    On Day 1 of the Maintenance period, participants who successfully completed the Induction period, were randomized to receive following intramuscular (IM) doses: Day 1 only: CAB long acting (LA) 800 mg (loading dose delivered as two 400 mg IM injections) + RPV LA 900 mg IM; Week 4 only: CAB LA 600 mg IM (second loading dose, no RPV); and from Week 8: CAB LA 600 mg IM +RPV LA 900 mg IM every 8 Weeks (Q8W) for 96 weeks. Eligible participants had the option to continue study participation in the Extension Period.

    Drug: CAB LA · Drug: RPV

  • Experimental
    CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period)

    On Day 1 of the Maintenance period, participants who successfully completed the Induction period, were randomized to receive following IM doses: Day 1 only: CAB LA 800 mg (loading dose delivered as two 400 mg IM injections) + RPV LA 600 mg IM; and from Week 4: CAB LA 400 mg IM + RPV LA 600 mg IM every 4 Weeks (Q4W) for 96 weeks. Eligible participants had the option to continue study participation in the Extension Period.

    Drug: CAB LA · Drug: RPV

  • Active comparator
    CAB 30 mg+ABC/3TC QD (Induction Period)

    In induction period, all participants received an oral regimen of cabotegravir (CAB) 30 milligrams (mg) once daily (QD) plus abacavir/lamivudine (ABC/3TC) 600/300 mg QD for 20 weeks. They also received an oral dose of Rilpivirine (RPV) 25 mg tablet once daily in the last 4 weeks of the Induction Period.

    Drug: CAB Oral Tablets · Drug: ABC/3TC Oral tablets · Drug: RPV Oral Tablets

  • Active comparator
    CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period)

    On Day 1 of the Maintenance period, participants who successfully completed the Induction period, were randomized to receive CAB and ABC/3TC QD for 96 weeks. Eligible participants had the option to continue study participation in Extension Period by switching to an optimized IM CAB LA+ RPV LA regimen of their choice (Q8W or Q4W).

    Drug: CAB Oral Tablets · Drug: ABC/3TC Oral tablets · Drug: RPV Oral Tablets

  • Experimental
    Optimized CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Extension Period)

    Participants who completed 96 weeks of CAB 30 mg + ABC/3TC QD regimen in Maintenance Period transitioned to Extension Period and received an optimized loading dose of CAB LA 600 mg+RPV LA 900 mg IM at Week 100 and Week 104 followed by CAB LA 600 mg+RPV LA 900 mg IM-Q8W in the Extension Phase. Participants were followed up until end of Extension Period.

    Drug: CAB LA · Drug: RPV

  • Experimental
    Optimized CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Extension Period)

    Participants who completed 96 weeks of CAB 30 mg + ABC/3TC QD regimen in Maintenance Period transitioned to Extension Period and received an optimized loading dose of CAB LA 400 mg+RPV LA 900 mg IM at Week 100 followed by CAB LA 400 mg+RPV LA 900 mg IM-Q8W in the Extension Phase. Participants were followed up until end of Extension Period.

    Drug: CAB LA · Drug: RPV

  • Other
    Long-Term Follow-Up Group

    This group included participants that were withdrawn from CAB LA+RPV LA IM regimens based on protocol criteria and were required to access Highly Active Antiretroviral Therapy (HAART) of choice. Participants were followed up for approximately 52 weeks.

    Other: HAART

Interventions

  • DrugCAB Oral Tablets

    White to almost white oval shaped film coated 30 mg tablets for oral administration.

  • DrugCAB LA

    Sterile white to slightly colored suspension containing 200 mg/mL of GSK744 as free acid (GSK1265744 free acid), polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection, packaged in a 3 mL USP Type I glass vial, for administration by IM injection

  • DrugABC/3TC Oral tablets

    ABC/3TC fixed dose combination (FDC) oral tablet, containing 600 mg of ABC (as abacavir sulfate) and 300 mg of 3TC

  • DrugRPV Oral Tablets

    Off-white, round, biconvex, film-coated 25 mg Rilpivirine (RPV) tablets for oral administration. Eligible subjects switching from the oral regimen to the IM regimen in the Extension Period will receive 2 weeks of RPV 25 mg once daily, from Week 102 through Week 104

  • OtherHAART

    Higly-active antiretroviral therapy chosen by participant based on investigator recommendations and based on availability.

  • DrugRPV

    Sterile white suspension containing 300 mg/mL of TMC278 as free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection, packaged in a 2 mL USP Type I glass vial, for administration by IM injection.

07

What researchers measure

Primary outcomes

  1. Percentage of Participants With Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) Level Below 50 Copies/Milliliter (c/mL) at Week 32

    Percentage of participants with HIV-1 RNA\<50 c/mL was obtained using Food and Drug Administration (FDA) Snapshot algorithm. The algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as well as participants who switch their concomitant antiretroviral therapy (ART) prior to the visit of interest as non-responders. The Intent-to-Treat Maintenance Exposed (ITT-ME) Population consisted of all randomized participants who received at least one injection or one dose of investigational product during the Maintenance Period of the study (on or after Day 1 visit).

    Time frame: Week 32

  2. Number of Participants With Protocol Defined Virologic Failure (PDVF) Until Week 32

    Virologic failure was defined as any of the following: (1) Non-response as indicated by a less than 1.0 logarithm to base 10 (log10) c/mL decrease in plasma HIV-1 RNA after 4 weeks of starting the Induction Period, which is subsequently confirmed, unless the plasma HIV-1 RNA is \< 400 c/mL; (2) Rebound as indicated by two consecutive plasma HIV-1 RNA levels \>=200 c/mL after prior suppression to \< 200 c/mL; (3) Rebound as indicated by two consecutive plasma HIV-1 RNA that are \> 0.5 log10 c/mL increase in plasma HIV-1 RNA from the nadir value on study, where the lowest HIV-1 RNA value is \>=200 c/mL.

    Time frame: Up to Week 32

  3. Number of Participants With Any Serious Adverse Event (SAE) and Any Non-serious Adverse Event (Non-SAE) (Induction Period)

    An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, important medical events which may require medical or surgical intervention, drug-induced liver injury with hyperbilirubinaemia.

    Time frame: Up to 20 weeks

  4. Number of Participants With Any Serious Adverse Event (SAE) and Any Non-serious Adverse Event (Non-SAE) (Maintenance Period)

    An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, important medical events which may require medical or surgical intervention, drug-induced liver injury with hyperbilirubinaemia. Data presented includes all post-baseline induction period and maintenance period adverse events, as well as long-term follow-up period adverse events for those participants who did not enter the extension period.

    Time frame: Up to an average of 59 weeks

  5. Number of Participants With Post-Baseline Adverse Events by Maximum Toxicity Grade

    An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Toxicity was graded according to Division of Acquired Immunodeficiency Syndrome (DAIDS) grading criteria, where Grade 1-mild, Grade 2-moderate, Grade 3-severe, Grade 4-potentially life-threatening. Data presented includes all post-baseline treatment emergent Induction Period and MP toxicities, as well as LTFP toxicities for those participants who did not enter the extension period. Number of participants with post-Baseline adverse events by maximum toxicity Grade have been presented.

    Time frame: Up to an average of 59 weeks

  6. Number of Participants With Maximum Post-Baseline Emergent Toxicities for Clinical Chemistry Parameters

    Clinical chemistry parameters aspartate amino transferase (AST), alanine amino transferase (ALT), alkaline phosphatase (ALP), carbon dioxide(CO2) content/bicarbonate (HCO3), cholesterol, creatine kinase (CK), glucose, low density lipoprotein (LDL) cholesterol, lipase, potassium, and sodium, total bilirubin (TBIL) and triglycerides were evaluated. Toxicity was graded according to Division of Acquired Immunodeficiency Syndrome (DAIDS) grading criteria, where Grade 1-mild, Grade 2-moderate, Grade 3-severe, Grade 4-potentially life-threatening. Data presented includes all post-baseline treatment emergent Induction Period and MP toxicities, as well as LTFP toxicities for those participants who did not enter the extension period. Number of participants with any time post-baseline maximum emergent toxicities in any of the chemistry parameters have been presented.

    Time frame: Up to an average of 59 weeks

  7. Number of Participants With Maximum Post-Baseline Emergent Toxicities for Hematology Parameters

    Hematology parameters hemoglobin, platelet count, total neutrophils and white blood cell count were evaluated. Toxicity was graded according to DAIDS grading criteria, where Grade 1-mild, Grade 2-moderate, Grade 3-severe, Grade 4-potentially life-threatening. Data presented includes all post-baseline treatment emergent Induction Period and MP toxicities, as well as LTFP toxicities for those participants who did not enter the extension period. Number of participants with any time post-baseline maximum emergent toxicities in any of the hematology parameters have been presented.

    Time frame: Up to an average of 59 weeks

  8. Number of Participants With Post-Baseline Urinalysis Dipstick Results

    Urinalysis dipstick included urine occult blood, urine glucose, urine ketones, urine nitrite, urine protein and urine leukocyte. The dipstick test gives results in a semi-quantitative manner and results for urinalysis parameters can be read as positive, trace, 1+, 2+ and 3+ indicating proportional concentrations in the urine sample. Data presented includes all post-baseline dipstick results during Induction and Maintenance Periods, as well as LTFP for those participants who did not enter the extension period.

    Time frame: Up to an average of 59 weeks

Secondary outcomes

  1. Percentage of Participants With Plasma HIV-1 RNA <200 c/mL and <50 c/mL, for Oral Dose of CAB 30 mg Plus ABC/3TC (Induction Period)

    Percentage of participants with HIV-1 RNA \<200 c/mL and \<50 c/mL for oral dose of CAB 30 mg plus ABC/3TC during Induction Period was obtained using FDA Snapshot algorithm. The algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as well as participants who switch their concomitant ART prior to the visit of interest, as non-responders. The Intent-to-Treat Exposed (ITT-E) Population consisted of all randomized participants who received at least one dose of investigational product.

    Time frame: Week -20, Week -16, Week -12, Week -8, Week -4, Day 1

  2. Absolute Values of Plasma HIV-1 RNA, for Oral Dose of CAB 30 mg Plus ABC/3TC (Induction Period)

    Plasma samples for quantitative HIV-1 RNA were collected at indicated time points. Log10 values for HIV-1 RNA have been presented.

    Time frame: Week -20, Week -16, Week -12, Week -8, Week -4, Day 1

  3. Change From Baseline in Plasma HIV-1 RNA, for Oral Dose of CAB 30 mg Plus ABC/3TC (Induction Period)

    Plasma samples for quantitative HIV-1 RNA were collected at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as: HIV-1 RNA(log 10) at post-baseline visit minus HIV-1 RNA(log 10) at Baseline.

    Time frame: Baseline (Week -20) and Week -16, Week -12, Week -8, Week -4, Day 1

  4. Absolute Values of Cluster of Differentiation 4+ (CD4+), for Oral Dose of CAB 30 mg Plus ABC/3TC (Induction Period)

    Blood samples were collected at specified time points to assess CD4+ using flow cytometry. Mean and standard deviation values for CD4+ are presented.

    Time frame: Week -20, Week -16, Week -12, Week -4, Day 1

  5. Change From Baseline in CD4+, for Oral Dose of CAB 30 mg Plus ABC/3TC (Induction Period)

    Blood samples were collected at specified time points to assess CD4+. It was evaluated by flow cytometry. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.

    Time frame: Baseline (Week -20) and Week -16, Week -12, Week -4, Day 1

  6. Number of Participants With AEs by Their Severity Grades, for Oral Dose of CAB 30 mg Plus ABC/3TC (Induction Period)

    An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Adverse events were evaluated by the investigator and graded according to the DAIDS toxicity grading, where Grade 1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening. The higher the grade, the more severe the symptoms. Number of participants with adverse events by maximum grade have been presented.

    Time frame: Up to 20 Weeks

  7. Number of Participants With Maximum Post-Baseline Emergent Toxicities for Hematology Parameters, for Oral Dose of CAB 30 mg Plus ABC/3TC (Induction Period)

    Hematology parameters hemoglobin, platelet count, total neutrophils and white blood cell count were evaluated. Laboratory toxicities were graded according to DAIDS grading criteria, where Grade 1-mild, Grade 2-moderate, Grade 3-severe, Grade 4-potentially life-threatening. Number of participants with any time post-baseline maximum emergent toxicities in any of the hematology parameters have been presented.

    Time frame: Up to Week 20

  8. Number of Participants With Maximum Post-Baseline Emergent Toxicities for Clinical Chemistry Parameters, for Oral Dose of CAB 30 mg Plus ABC/3TC (Induction Period)

    Clinical chemistry parameters AST, ALT, ALP, CO2/HCO3, cholesterol, CK, glucose, LDL cholesterol, lipase, potassium, and sodium, total TBIL and triglycerides were evaluated. Laboratory toxicities were graded according to DAIDS grading criteria, where Grade 1-mild, Grade 2-moderate, Grade 3-severe, Grade 4-potentially life-threatening. Number of participants with any time post-baseline maximum emergent toxicities in any of the chemistry parameters have been presented.

    Time frame: Up to 20 weeks

  9. Change From Baseline in Clinical Chemistry Parameters: ALT, ALP, AST and CK (Induction Period)

    Blood samples were collected for the analysis of clinical chemistry parameters including ALT, ALP, AST and CK at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.

    Time frame: Baseline (Week -20) and Week -16, Week -12, Week -8, Week -4, Day 1

  10. Change From Baseline in Clinical Chemistry Parameter: Albumin (Induction Period)

    Blood samples were collected for the analysis of clinical chemistry parameter: Albumin at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.

    Time frame: Baseline (Week -20) and Week -16, Week -12, Week -8, Week -4, Day 1

  11. Change From Baseline in Clinical Chemistry Parameters: Total Bilirubin and Creatinine (Induction Period)

    Blood samples were collected for the analysis of clinical chemistry parameters including total Bilirubin and Creatinine at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.

    Time frame: Baseline (Week -20) and Week -16, Week -12, Week -8, Week -4, Day 1

  12. Change From Baseline in Clinical Chemistry Parameters: CO2, Chloride, Cholesterol, Glucose, Potassium, Sodium, Triglyceride and Urea (Induction Period)

    Blood samples were collected for the analysis of clinical chemistry parameters including total CO2, chloride, cholesterol, glucose, potassium, sodium, triglyceride and urea at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.

    Time frame: Baseline (Week -20) and Week -16, Week -12, Week -8, Week -4, Day 1

  13. Change From Baseline in Clinical Chemistry Parameter: Lipase (Induction Period)

    Blood samples were collected for the analysis of clinical chemistry parameter: Lipase at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.

    Time frame: Baseline (Week -20) and Week -16, Week -12, Week -8, Week -4, Day 1

  14. Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Lymphocytes, Total Neutrophils, Monocytes, Platelets Count and White Blood Cells (WBC) Count (Induction Period)

    Blood samples were collected for the analysis of hematology parameters: Basophil, Eosinophils, Lymphocytes, Total Neutrophils, Monocytes, Platelets count and WBC at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.

    Time frame: Baseline (Week -20) and Week -16, Week -12, Week -8, Week -4, Day 1

  15. Change From Baseline in Hematology Parameter: Hematocrit (Induction Period)

    Blood samples were collected for the analysis of hematology parameter: Hematocrit at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.

    Time frame: Baseline (Week -20) and Week -16, Week -12, Week -8, Week -4, Day 1

  16. Change From Baseline in Hematology Parameter: Hemoglobin (Induction Period)

    Blood samples were collected for the analysis of hematology parameter: Hemoglobin at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.

    Time frame: Baseline (Week -20) and Week -16, Week -12, Week -8, Week -4, Day 1

  17. Change From Baseline in Hematology Parameter: Mean Corpuscle Volume (Induction Period)

    Blood samples were collected for the analysis of hematology parameter: Mean Corpuscle Volume at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.

    Time frame: Baseline (Week -20) and Week -16, Week -12, Week -8, Week -4, Day 1

  18. Change From Baseline in Hematology Parameter: Red Blood Cell Count (Induction Period)

    Blood samples were collected for the analysis of hematology parameter: Red Blood Cell count at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.

    Time frame: Baseline (Week -20) and Week -16, Week -12, Week -8, Week -4, Day 1

  19. Percentage of Participants With Plasma HIV-1 RNA Level <50 c/mL and <200 c/mL Over Week 96 (Maintenance Period)

    Percentage of participants with HIV-1 RNA \<50 c/mL and \<200 c/mL was obtained using FDA Snapshot algorithm. The algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as well as participants who switch their concomitant ART prior to the visit of interest, as non-responders.

    Time frame: From Day 1 up to Week 96

  20. Number of Participants With Protocol Defined Virologic Failure at Week 32 and Week 48 (Maintenance Period)

    Virologic failure was defined as any of the following: (1) Non-response as indicated by a less than a 1.0 log10 c/mL decrease in plasma HIV-1 RNA after 4 weeks of starting the Induction Period, which is subsequently confirmed, unless the plasma HIV-1 RNA is \< 400 c/mL; (2) Rebound as indicated by two consecutive plasma HIV-1 RNA levels \>=200 c/mL after prior suppression to \< 200 c/mL; (3) Rebound as indicated by two consecutive plasma HIV-1 RNA that are \> 0.5 log10 c/mL increase in plasma HIV-1 RNA from the nadir value on study, where the lowest HIV-1 RNA value is \>=200 c/mL.

    Time frame: At Week 32 and Week 48

  21. Absolute Value of Plasma HIV-1 RNA at Week 32 and Week 96 (Maintenance Period)

    Plasma samples for quantitative HIV-1 RNA analysis were collected at indicated time points during Maintenance Period. Log10 values for HIV-1 RNA have been presented. SD=0.000 is defined as following: if participants analyzed at a specific timepoint have resulted same values, then SD is considered equal with 0.000.

    Time frame: At Week 32 and Week 96

  22. Change From Baseline in Plasma HIV-1 RNA at Week 32 and Week 96 (Maintenance Period)

    Plasma samples for quantitative HIV-1 RNA analysis were collected at indicated time points during Maintenance Period. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as: HIV-1 RNA(log 10) at post-baseline visit minus HIV-1 RNA(log 10) at Baseline.

    Time frame: At Week 32 and Week 96 (compared with Baseline [Week -20])

  23. Absolute Value of CD4+ at Week 32 and Week 96 (Maintenance Period)

    Blood samples were collected at specified time points to assess CD4+. It was evaluated by flow cytometry.

    Time frame: At Week 32 and Week 96

  24. Change From Baseline in CD4+ at Week 32 and Week 96 (Maintenance Period)

    Blood samples were collected at specified time points to assess CD4+. It was evaluated by flow cytometry. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as post-baseline value minus Baseline value.

    Time frame: At Week 32 and Week 96 (compared with Baseline [Week -20])

  25. Number of Participants With HIV-1 Disease Progression Over Week 32 and Week 96 (Maintenance Period)

    HIV-associated conditions were recorded during the study and was assessed according to the Centers for Disease Control and Prevention (CDC) Classification System for HIV Infection in Adults. The clinical categories of HIV infection as per CDC system are class A=Asymptomatic HIV infection or lymphadenopathy or acute HIV infection; class B=symptomatic non-acquired immunodeficiency syndrome (AIDS) conditions and class C=AIDS indicator conditions. Number of participants experiencing disease progression is presented, where disease progression is defined as the progression from Baseline HIV disease status as follows: CDC class A at Baseline to CDC class C event; CDC Class B at Baseline to CDC Class C event; CDC Class C at Baseline to new CDC Class C event; and CDC class A, B or C at Baseline to death.

    Time frame: At Week 32 and Week 96

  26. Number of Participants With AEs by Their Severity Grades Over Week 32 (Maintenance Period)

    An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Adverse events were evaluated by the investigator and graded according to the DAIDS toxicity grading, where Grade 1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening). The higher the grade, the more severe the symptoms. Number of participants with adverse events by maximum grade have been presented.

    Time frame: Up to Week 32

  27. Number of Participants With AEs by Their Severity Grades Over Week 96 (Maintenance Period)

    An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Adverse events were evaluated by the investigator and graded according to the DAIDS toxicity grading, where Grade 1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening). The higher the grade, the more severe the symptoms. Number of participants with adverse events by maximum grade have been presented.

    Time frame: Up to Week 96

  28. Change From Baseline in Clinical Chemistry Parameters: ALT, ALP, AST and CK at Week 32 and Week 96 (Maintenance Period)

    Blood samples were collected for the analysis of clinical chemistry parameters including ALT, ALP, AST and CK at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.

    Time frame: At Week 32 and Week 96 (compared with Baseline [Week -20])

  29. Change From Baseline in Clinical Chemistry Parameter: Albumin at Week 32 and Week 96 (Maintenance Period)

    Blood samples were collected for the analysis of clinical chemistry parameters including Albumin at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.

    Time frame: At Week 32 and Week 96 (compared with Baseline [Week -20])

  30. Change From Baseline in Clinical Chemistry Parameters: Total Bilirubin and Creatinine at Week 32 and Week 96 (Maintenance Period)

    Blood samples were collected for the analysis of clinical chemistry parameters including Total Bilirubin and Creatinine at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.

    Time frame: At Week 32 and Week 96 (compared with Baseline [Week -20])

  31. Change From Baseline in Clinical Chemistry Parameters: Total CO2, Chloride, Cholesterol, Glucose, Potassium, Sodium, Triglyceride and Urea at Week 32 and Week 96 (Maintenance Period)

    Blood samples were collected for the analysis of clinical chemistry parameters including total CO2, chloride, cholesterol, glucose, potassium, sodium, triglyceride and urea at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.

    Time frame: At Week 32 and Week 96 (compared with Baseline [Week -20])

  32. Change From Baseline in Clinical Chemistry Parameter: Lipase at Week 32 and Week 96 (Maintenance Period)

    Blood samples were collected for the analysis of clinical chemistry parameters including Lipase at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.

    Time frame: At Week 32 and Week 96 (compared with Baseline [Week -20])

  33. Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Lymphocytes, Total Neutrophils, Monocytes, Platelet Count and WBC Count at Week 32 and Week 96 (Maintenance Period)

    Blood samples were collected for the analysis of hematology parameters including Basophil, Eosinophils, Lymphocytes, Total Neutrophils, Monocytes, Platelet count and WBC count at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.

    Time frame: At Week 32 and Week 96 (compared with Baseline [Week -20])

  34. Change From Baseline in Hematology Parameter: Hematocrit at Week 32 and Week 96 (Maintenance Period)

    Blood samples were collected for the analysis of hematology parameters including Hematocrit at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.

    Time frame: At Week 32 and Week 96 (compared with Baseline [Week -20])

  35. Change From Baseline in Hematology Parameter: Hemoglobin at Week 32 and Week 96 (Maintenance Period)

    Blood samples were collected for the analysis of hematology parameters including Hemoglobin at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.

    Time frame: At Week 32 and Week 96 (compared with Baseline [Week -20])

  36. Change From Baseline in Hematology Parameter: Mean Corpuscle Volume at Week 32 and Week 96 (Maintenance Period)

    Blood samples were collected for the analysis of hematology parameters including Mean Corpuscle Volume at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.

    Time frame: At Week 32 and Week 96 (compared with Baseline [Week -20])

  37. Change From Baseline in Hematology Parameter: Red Blood Cell Count at Week 32 and Week 96 (Maintenance Period)

    Blood samples were collected for the analysis of hematology parameters including Red Blood Cell count at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.

    Time frame: At Week 32 and Week 96 (compared with Baseline [Week -20])

  38. Average Initial Concentration (C0) and Maximum Plasma Concentration (Cmax) of CAB LA (Q4W IM and Q8W IM Dosing) (Maintenance Period)

    Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of CAB LA. The PK Concentration Population included all participants who received CAB LA and/or RPV LA and underwent PK sampling during the study, and provided available CAB LA and/or RPV LA plasma concentration data.

    Time frame: Up to Week 32

  39. Average Initial Concentration (C0) and Cmax of RPV LA (Q4W IM and Q8W IM Dosing) (Maintenance Period)

    Blood samples were collected at indicated time points for PK analysis of RPV LA. C0 and Cmax of RPV LA (Q4W IM and Q8W IM dosing) was evaluated.

    Time frame: Up to Week 32

  40. Trough Concentration (Ctrough) of CAB LA (Q8W IM Dosing) Used for Assessment of Steady State (Maintenance Period)

    Blood samples were collected at indicated time points for PK analysis of CAB LA. Ctrough is the lowest concentration reached by a drug before the next dose is administered. Ctrough for CAB LA (Q8W IM dosing) which were considered for the assessment of steady state are presented.

    Time frame: Pre-dose on Weeks 16, 24 and 32

  41. Ctrough of CAB LA (Q4W IM Dosing) Used for Assessment of Steady State (Maintenance Period)

    Blood samples were collected at indicated time points for PK analysis of CAB LA. Ctrough is the lowest concentration reached by a drug before the next dose is administered. Ctrough for CAB LA (Q4W IM dosing) which were considered for the assessment of steady state are presented.

    Time frame: Pre-dose on Weeks 16, 20, 24, 28 and 32

  42. Ctrough of RPV LA (Q8W IM Dosing) Used for Assessment of Steady State (Maintenance Period)

    Blood samples were collected at indicated time points for PK analysis of RPV LA. Ctrough is the lowest concentration reached by a drug before the next dose is administered. Ctrough for RPV LA (Q8W IM dosing) which were considered for the assessment of steady state are presented.

    Time frame: Pre-dose on Weeks 16, 24 and 32

  43. Ctrough of RPV LA (Q4W IM Dosing) Used for Assessment of Steady State (Maintenance Period)

    Blood samples were collected at indicated time points for PK analysis of RPV LA. Ctrough is the lowest concentration reached by a drug before the next dose is administered. Ctrough for RPV LA (Q4W IM dosing) which were considered for the assessment of steady state are presented.

    Time frame: Pre-dose on Weeks 16, 20, 24, 28 and 32

  44. Pharmacodynamic Response (HIV-1 RNA<50 c/mL) in Relation With PK Parameter (AUC[0-tau]) of CAB LA and RPV LA at Week 32 (Maintenance Period)

    Logistic regression was used to examine the correlation between pharmacodynamics response (HIV-1 RNA\<50 c/mL) at Week 32 and plasma PK parameter: area under plasma concentration-time curve from time zero to the end of dosing interval (AUC \[0-tau\]) of CAB LA and RPV LA per arm using MSDF (Missing, Switch or Discontinuation = Failure) algorithm. Estimates were obtained from logistic statistical model where the dependent variable is "HIV-1 RNA\<50 c/mL" (success) and the independent variable is PK parameter (AUC \[0-tau\]). Slopes and standard error are presented. Estimated effect represents the change in log odds for a one-unit increase in the PK parameter AUC (0-tau). Standard Error (SE)=0.000 is defined as following: if for all participants was resulted same value for the specific timepoint, then SE is equal with 0.000 .

    Time frame: Up to Week 32

  45. Pharmacodynamic Response (HIV-1 RNA<50 c/mL) in Relation With PK Parameter (Average C0) of CAB LA and RPV LA at Week 32 (Maintenance Period)

    Logistic regression was used to examine the correlation between pharmacodynamics response (HIV-1 RNA\<50 c/mL) at Week 32 and plasma PK parameter: Average C0 of CAB LA and RPV LA per arm using MSDF (Missing, Switch or Discontinuation = Failure) algorithm. Estimates were obtained from logistic statistical model where the dependent variable is "HIV-1 RNA\<50 c/mL" (success) and the independent variable is PK parameter (Average C0). Slopes and standard error are presented. Estimated effect represents the change in log odds for a one-unit increase in the PK parameter Average C0.

    Time frame: Up to Week 32

  46. Pharmacodynamic Response (HIV-1 RNA<50 c/mL) in Relation With PK Parameter (Cmax) of CAB LA and RPV LA at Week 32 (Maintenance Period)

    Logistic regression was used to examine the correlation between pharmacodynamics response (HIV-1 RNA\<50 c/mL) at Week 32 and plasma PK parameter: Cmax of CAB LA and RPV LA per arm using MSDF (Missing, Switch or Discontinuation = Failure) algorithm. Estimates were obtained from logistic statistical model where the dependent variable is "HIV-1 RNA\<50 c/mL" (success) and the independent variable is PK parameter (Cmax). Slopes and standard error are presented. Estimated effect represents the change in log odds for a one-unit increase in the PK parameter Cmax.

    Time frame: Up to Week 32

  47. Virologic Failure (From MSDF Algorithm) in Relation With PK Parameter (AUC[0-tau]) of CAB LA and RPV LA at Week 32 (Maintenance Period)

    Logistic regression was used to examine the correlation between virologic failure at Week 32 and plasma PK parameter: AUC (0-tau) of CAB LA and RPV LA per arm using MSDF (Missing, Switch or Discontinuation = Failure) algorithm. Estimates were obtained from logistic statistical model where the dependent variable is "virologic failure" and the independent variable is PK parameter (AUC \[0-tau\]). Slopes and standard error are presented. Estimated effect represents the change in log odds for a one-unit increase in the PK parameter AUC (0-tau). SE=0.000 is defined as following: if for all participants was resulted same value for the specific timepoint, then SE is equal with 0.000.

    Time frame: Up to Week 32

  48. Virologic Failure (From MSDF Algorithm) in Relation With PK Parameter (Average C0) of CAB LA and RPV LA at Week 32 (Maintenance Period)

    Logistic regression was used to examine the correlation between virologic failure at Week 32 and plasma PK parameter: Average C0 of CAB LA and RPV LA per arm using MSDF (Missing, Switch or Discontinuation = Failure) algorithm. Estimates were obtained from logistic statistical model where the dependent variable is "virologic failure" and the independent variable is PK parameter (Average C0). Slopes and standard error are presented. Estimated effect represents the change in log odds for a one-unit increase in the PK parameter Average C0.

    Time frame: Up to Week 32

  49. Virologic Failure (From MSDF Algorithm) in Relation With PK Parameter (Cmax) of CAB LA and RPV LA at Week 32 (Maintenance Period)

    Logistic regression was used to examine the correlation between virologic failure at Week 32 and plasma PK parameter: Cmax of CAB LA and RPV LA per arm using MSDF (Missing, Switch or Discontinuation = Failure) algorithm. Estimates were obtained from logistic statistical model where the dependent variable is "virologic failure" and the independent variable is PK parameter (Cmax). Slopes and standard error are presented. Estimated effect represents the change in log odds for a one-unit increase in the PK parameter Cmax.

    Time frame: Up to Week 32

  50. Number of Participants With Treatment-emergent Genotypic Resistance

    Plasma samples were collected to assess treatment emergent Genotypic Resistance for participants who had confirmed virologic failure. Number of participants who had any Integrase Inhibitor (INI) mutations or major mutations of other classes (Nucleoside reverse transcriptase inhibitor \[NRTI\], Non-nucleoside reverse transcriptase inhibitor \[NNRTI\], protease inhibitor \[PI\])are presented.

    Time frame: Up to Week 32

  51. Number of Participants With Treatment-emergent Phenotypic Resistance

    Plasma samples were collected for drug resistance testing. Number of participants, with treatment emergent phenotypic resistance to INI, NNRTI, NRTI and/or PI were summarized. Overall susceptibility of the drug was categorized as sensitive, partially sensitive and resistant.

    Time frame: Up to Week 32

  52. Percentage of Participants With Plasma HIV-1 RNA Level <50 c/mL Over Week 32 by Subgroups (Maintenance Period)

    Percentage of participants with HIV-1 RNA\<50 c/mL was obtained using FDA Snapshot algorithm. The algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as well as participants who switch their concomitant ART prior to the visit of interest, as non-responders. Data is presented for following subgroups: Baseline plasma HIV-1 RNA levels, Baseline CD4+ cell count, Race and HIV Risk factor (Homosexual contact \[HC\] and not injectable drug user).

    Time frame: Up to Week 32

  53. Percentage of Participants With Protocol Defined Virologic Failure (PDVF) at Week 32 by Subgroups(Maintenance Period)

    Virologic failure was defined as any of the following: (1) Non-response as indicated by a less than a 1.0 log10 c/mL decrease in plasma HIV-1 RNA after 4 weeks of starting the Induction Period, which is subsequently confirmed, unless the plasma HIV-1 RNA is \< 400 c/mL; (2) Rebound as indicated by two consecutive plasma HIV-1 RNA levels \>=200 c/mL after prior suppression to \<200 c/mL; (3) Rebound as indicated by two consecutive plasma HIV-1 RNA that are \> 0.5 log10 c/mL increase in plasma HIV-1 RNA from the nadir value on study, where the lowest HIV-1 RNA value is \>=200 c/mL. Data is presented for following subgroups: Baseline plasma HIV-1 RNA levels, Baseline CD4+ cell count, Race and HIV Risk factor (Homosexual contact \[HC\] and not injectable drug user).

    Time frame: Up to Week 32

  54. HIV Treatment Satisfaction Questionnaire - Status Version (HIVTSQ[s]) Total Score at Week 32 and Week 96 (Maintenance Period)

    The HIVTSQ(s) was developed to evaluate treatments for HIV and participant satisfaction. It has total 14 items and each items are scored from 6 (very satisfied) to 0 (very dissatisfied). Items 1 to 12 are summed to produce the Total Treatment Satisfaction Score with a possible range of 0 to 72. Higher scores represent greater treatment satisfaction as compared to the past few weeks.

    Time frame: At Week 32 and Week 96

  55. HIV Treatment Satisfaction Questionnaire - Change Version (HIVTSQ[c]) Total Score at Week 32 (Maintenance Period)

    The HIVTSQ(c) was developed to evaluate treatments for HIV and participant satisfaction. It has total 14 items and each items are scored from +3 ('much more satisfied', 'much more convenient', 'much more flexible', etc.) to -3 ('much less satisfied', 'much less convenient', 'much less flexible', etc.). Items 1 to 12 (excluding Items 7b and 9b) are summed to produce a Total Treatment Satisfaction Score (change) with a possible range of -33 to +33. The higher the score, the greater the improvement in satisfaction with treatment; the lower the score, the greater the deterioration in satisfaction with treatment.

    Time frame: Week 32

  56. Number of Participants With HIV Medication Questionnaire (HIVMQ) Item E and F Scores at Week 32 (Maintenance Period)

    The HIVMQ was developed to assess participant reported medication adherence. It has 6 items (a, b, c, d, e, f). Item E (How often do you find it inconvenient or difficult to take/receive medication as recommended?) and Item F (How much pain/discomfort have experienced with this medication?). Each of these 2 items are scored from 0 (none of the time) to 6 (all of the time). The higher the score, the greater the adherence to medication. Number of participants with HIVMQ Item E and F Scores at Week 32 by their score categories (0: none of the time to 6: all of the time) are presented.

    Time frame: Week 32

  57. Number of Participants With HIV Medication Questionnaire (HIVMQ) Item E and F Scores at Week 96 (Maintenance Period)

    The HIVMQ was developed to assess participant reported medication adherence. It has 6 items (a, b, c, d, e, f). Item E (How often do you find it inconvenient or difficult to take/receive medication as recommended?) and Item F (How much pain/discomfort have experienced with this medication?). Each of these 2 items are scored from 0 (none of the time) to 6 (all of the time). The higher the score, the greater the adherence to medication. Number of participants with HIVMQ Item E and F Scores at Week 96 by their score categories (0: none of the time to 6: all of the time) are presented.

    Time frame: Week 96

08

Results

Posted Aug 31, 2020

Participant flow

The study was conducted across 50 sites in five countries (United States, Canada, France, Germany and Spain). The results presented are based on final analysis, up to approximately Week 468.

Induction Period (20 Weeks)
Participant flow — Induction Period (20 Weeks)
MilestoneCAB 30 mg+ABC/3TC QD (Induction Period)CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period)CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period)CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period)Optimized CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Extension Period)Optimized CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Extension Period)Long-Term Follow-Up Group
Started309000000
Completed288000000
Not completed21000000
Withdrew: Adverse event3000000
Withdrew: Lack of efficacy5000000
Withdrew: Protocol violation2000000
Withdrew: Met protocol-defined stopping criteria3000000
Withdrew: Lost to follow-up2000000
Withdrew: Withdrawal by subject5000000
Withdrew: Physician decision1000000
Maintenance Period (Up to Week 96)
Participant flow — Maintenance Period (Up to Week 96)
MilestoneCAB 30 mg+ABC/3TC QD (Induction Period)CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period)CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period)CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period)Optimized CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Extension Period)Optimized CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Extension Period)Long-Term Follow-Up Group
Started011511556000
Completed011010147000
Not completed05149000
Withdrew: Adverse event0181000
Withdrew: Lack of efficacy0101000
Withdrew: Protocol violation0120000
Withdrew: Met protocol-defined stopping criteria0011000
Withdrew: Lost to follow-up0001000
Withdrew: Withdrawal by subject0135000
Withdrew: Physician decision0100000
Extension Period (Week 97 to Study End)
Participant flow — Extension Period (Week 97 to Study End)
MilestoneCAB 30 mg+ABC/3TC QD (Induction Period)CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period)CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period)CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period)Optimized CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Extension Period)Optimized CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Extension Period)Long-Term Follow-Up Group
Started0107101034100
Completed0927602680
Not completed015250820
Withdrew: Adverse event03110210
Withdrew: Lack of efficacy0000100
Withdrew: Protocol violation0110200
Withdrew: Withdrawal by subject0790200
Withdrew: Lost to follow-up0210100
Withdrew: Physician decision0220000
Withdrew: Site closed0010010
Long-Term Follow-up Period (52 Weeks)
Participant flow — Long-Term Follow-up Period (52 Weeks)
MilestoneCAB 30 mg+ABC/3TC QD (Induction Period)CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period)CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period)CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period)Optimized CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Extension Period)Optimized CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Extension Period)Long-Term Follow-Up Group
Started00000043
Completed00000037
Not completed0000006
Withdrew: Other0000006

Outcome measures

PrimaryPercentage of Participants With Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) Level Below 50 Copies/Milliliter (c/mL) at Week 32

Percentage of participants with HIV-1 RNA\<50 c/mL was obtained using Food and Drug Administration (FDA) Snapshot algorithm. The algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as well as participants who switch their concomitant antiretroviral therapy (ART) prior to the visit of interest as non-responders. The Intent-to-Treat Maintenance Exposed (ITT-ME) Population consisted of all randomized participants who received at least one injection or one dose of investigational product during the Maintenance Period of the study (on or after Day 1 visit).

Time frame:
Week 32
Reported as:
Number · Percentage of participants
Percentage of Participants With Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) Level Below 50 Copies/Milliliter (c/mL) at Week 32
Percentage of participantsCAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period)CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period)CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period)
Percentage of Participants With Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) Level Below 50 Copies/Milliliter (c/mL) at Week 32959491
Statistical analysis
  • CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period) vs CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period) · Difference in percentage: 3.7 · 95% CI -4.8 to 12.2Comparison between CAB LA 600 mg+RPV LA 900 mg IM-Q8W and CAB 30 mg+ABC/3TC QD
  • CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period) vs CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period) · Difference in percentage: 2.8 · 95% CI -5.8 to 11.5Comparison between CAB LA 400 mg+RPV LA 600 mg IM-Q4W and CAB 30 mg+ABC/3TC QD
PrimaryNumber of Participants With Protocol Defined Virologic Failure (PDVF) Until Week 32

Virologic failure was defined as any of the following: (1) Non-response as indicated by a less than 1.0 logarithm to base 10 (log10) c/mL decrease in plasma HIV-1 RNA after 4 weeks of starting the Induction Period, which is subsequently confirmed, unless the plasma HIV-1 RNA is \< 400 c/mL; (2) Rebound as indicated by two consecutive plasma HIV-1 RNA levels \>=200 c/mL after prior suppression to \< 200 c/mL; (3) Rebound as indicated by two consecutive plasma HIV-1 RNA that are \> 0.5 log10 c/mL increase in plasma HIV-1 RNA from the nadir value on study, where the lowest HIV-1 RNA value is \>=200 c/mL.

Time frame:
Up to Week 32
Reported as:
Count of participants · Participants
Number of Participants With Protocol Defined Virologic Failure (PDVF) Until Week 32
ParticipantsCAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period)CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period)CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period)
Number of Participants With Protocol Defined Virologic Failure (PDVF) Until Week 32101
PrimaryNumber of Participants With Any Serious Adverse Event (SAE) and Any Non-serious Adverse Event (Non-SAE) (Induction Period)

An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, important medical events which may require medical or surgical intervention, drug-induced liver injury with hyperbilirubinaemia.

Time frame:
Up to 20 weeks
Reported as:
Count of participants · Participants
Number of Participants With Any Serious Adverse Event (SAE) and Any Non-serious Adverse Event (Non-SAE) (Induction Period)
ParticipantsCAB 30 mg+ABC/3TC QD (Induction Period)
Any non-SAE246
Any SAE8
PrimaryNumber of Participants With Any Serious Adverse Event (SAE) and Any Non-serious Adverse Event (Non-SAE) (Maintenance Period)

An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, important medical events which may require medical or surgical intervention, drug-induced liver injury with hyperbilirubinaemia. Data presented includes all post-baseline induction period and maintenance period adverse events, as well as long-term follow-up period adverse events for those participants who did not enter the extension period.

Time frame:
Up to an average of 59 weeks
Reported as:
Count of participants · Participants
Number of Participants With Any Serious Adverse Event (SAE) and Any Non-serious Adverse Event (Non-SAE) (Maintenance Period)
ParticipantsCAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period)CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period)CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period)
Any non-SAE11511352
Any SAE985
PrimaryNumber of Participants With Post-Baseline Adverse Events by Maximum Toxicity Grade

An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Toxicity was graded according to Division of Acquired Immunodeficiency Syndrome (DAIDS) grading criteria, where Grade 1-mild, Grade 2-moderate, Grade 3-severe, Grade 4-potentially life-threatening. Data presented includes all post-baseline treatment emergent Induction Period and MP toxicities, as well as LTFP toxicities for those participants who did not enter the extension period. Number of participants with post-Baseline adverse events by maximum toxicity Grade have been presented.

Time frame:
Up to an average of 59 weeks
Reported as:
Count of participants · Participants
Number of Participants With Post-Baseline Adverse Events by Maximum Toxicity Grade
ParticipantsCAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period)CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period)CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period)
Any AE with maximum toxicity Grade 1312519
Any AE with maximum toxicity Grade 2677229
Any AE with maximum toxicity Grade 315143
Any AE with maximum toxicity Grade 4221
PrimaryNumber of Participants With Maximum Post-Baseline Emergent Toxicities for Clinical Chemistry Parameters

Clinical chemistry parameters aspartate amino transferase (AST), alanine amino transferase (ALT), alkaline phosphatase (ALP), carbon dioxide(CO2) content/bicarbonate (HCO3), cholesterol, creatine kinase (CK), glucose, low density lipoprotein (LDL) cholesterol, lipase, potassium, and sodium, total bilirubin (TBIL) and triglycerides were evaluated. Toxicity was graded according to Division of Acquired Immunodeficiency Syndrome (DAIDS) grading criteria, where Grade 1-mild, Grade 2-moderate, Grade 3-severe, Grade 4-potentially life-threatening. Data presented includes all post-baseline treatment emergent Induction Period and MP toxicities, as well as LTFP toxicities for those participants who did not enter the extension period. Number of participants with any time post-baseline maximum emergent toxicities in any of the chemistry parameters have been presented.

Time frame:
Up to an average of 59 weeks
Reported as:
Count of participants · Participants
Number of Participants With Maximum Post-Baseline Emergent Toxicities for Clinical Chemistry Parameters
ParticipantsCAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period)CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period)CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period)
Maximum toxicity Grade 1949444
Maximum toxicity Grade 2504216
Maximum toxicity Grade 3152010
Maximum toxicity Grade 41072
PrimaryNumber of Participants With Maximum Post-Baseline Emergent Toxicities for Hematology Parameters

Hematology parameters hemoglobin, platelet count, total neutrophils and white blood cell count were evaluated. Toxicity was graded according to DAIDS grading criteria, where Grade 1-mild, Grade 2-moderate, Grade 3-severe, Grade 4-potentially life-threatening. Data presented includes all post-baseline treatment emergent Induction Period and MP toxicities, as well as LTFP toxicities for those participants who did not enter the extension period. Number of participants with any time post-baseline maximum emergent toxicities in any of the hematology parameters have been presented.

Time frame:
Up to an average of 59 weeks
Reported as:
Count of participants · Participants
Number of Participants With Maximum Post-Baseline Emergent Toxicities for Hematology Parameters
ParticipantsCAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period)CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period)CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period)
Maximum toxicity Grade 123177
Maximum toxicity Grade 2242
Maximum toxicity Grade 3002
Maximum toxicity Grade 4030
PrimaryNumber of Participants With Post-Baseline Urinalysis Dipstick Results

Urinalysis dipstick included urine occult blood, urine glucose, urine ketones, urine nitrite, urine protein and urine leukocyte. The dipstick test gives results in a semi-quantitative manner and results for urinalysis parameters can be read as positive, trace, 1+, 2+ and 3+ indicating proportional concentrations in the urine sample. Data presented includes all post-baseline dipstick results during Induction and Maintenance Periods, as well as LTFP for those participants who did not enter the extension period.

Time frame:
Up to an average of 59 weeks
Reported as:
Count of participants · Participants
Number of Participants With Post-Baseline Urinalysis Dipstick Results
ParticipantsCAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period)CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period)CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period)
Urine Occult Blood, Trace, n=10,11,4561
Urine Occult Blood, 1+, n=10,11,4332
Urine Occult Blood, 2+, n=10,11,4000
Urine Occult Blood, 3+, n=10,11,4221
Urine Occult Blood, Positive, n=10,11,4000
Urine Glucose, Trace, n=1,1,1100
Urine Glucose, 1+, n=1,1,1001
Urine Glucose, 2+, n=1,1,1010
Urine Glucose, 3+, n=1,1,1000
Urine Glucose, Positive, n=1,1,1000
Urine Ketones, Trace, n=16,20,1012178
Urine Ketones, 1+, n=16,20,10432
Urine Ketones, 2+, n=16,20,10000
Urine Ketones, 3+, n=16,20,10000
Urine Ketones, Positive, n=16,20,10000
Urine Nitrite, Trace, n=1,3,1000
Urine Nitrite, 1+, n=1,3,1000
Urine Nitrite, 2+, n=1,3,1000
Urine Nitrite, 3+, n=1,3,1000
Urine Nitrite, Positive, n=1,3,1131
Urine Protein, Trace, n=17,17,715112
Urine Protein, 1+, n=17,17,7245
Urine Protein, 2+, n=17,17,7020
Urine Protein, 3+, n=17,17,7000
Urine Protein, Positive, n=17,17,7000
Urine Leukocyte, Trace, n=20,20,88103
Urine Leukocyte, 1+, n=20,20,8783
Urine Leukocyte, 2+, n=20,20,8401
Urine Leukocyte, 3+, n=20,20,8121
Urine Leukocyte, Positive, n=20,20,8000
SecondaryPercentage of Participants With Plasma HIV-1 RNA <200 c/mL and <50 c/mL, for Oral Dose of CAB 30 mg Plus ABC/3TC (Induction Period)

Percentage of participants with HIV-1 RNA \<200 c/mL and \<50 c/mL for oral dose of CAB 30 mg plus ABC/3TC during Induction Period was obtained using FDA Snapshot algorithm. The algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as well as participants who switch their concomitant ART prior to the visit of interest, as non-responders. The Intent-to-Treat Exposed (ITT-E) Population consisted of all randomized participants who received at least one dose of investigational product.

Time frame:
Week -20, Week -16, Week -12, Week -8, Week -4, Day 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Plasma HIV-1 RNA <200 c/mL and <50 c/mL, for Oral Dose of CAB 30 mg Plus ABC/3TC (Induction Period)
Percentage of participantsCAB 30 mg+ABC/3TC QD (Induction Period)
HIV-1 RNA<50 c/mL, Week -200
HIV-1 RNA<50 c/mL, Week -1672
HIV-1 RNA<50 c/mL, Week -1290
HIV-1 RNA<50 c/mL, Week -889
HIV-1 RNA<50 c/mL, Week -492
HIV-1 RNA<50 c/mL, Day 191
HIV-1 RNA<200 c/mL, Week -200
HIV-1 RNA<200 c/mL, Week -1694
HIV-1 RNA<200 c/mL, Week -1297
HIV-1 RNA<200 c/mL, Week -896
HIV-1 RNA<200 c/mL, Week -494
HIV-1 RNA<200 c/mL, Day 194
SecondaryAbsolute Values of Plasma HIV-1 RNA, for Oral Dose of CAB 30 mg Plus ABC/3TC (Induction Period)

Plasma samples for quantitative HIV-1 RNA were collected at indicated time points. Log10 values for HIV-1 RNA have been presented.

Time frame:
Week -20, Week -16, Week -12, Week -8, Week -4, Day 1
Reported as:
Mean · Log10 copies per milliliter
Absolute Values of Plasma HIV-1 RNA, for Oral Dose of CAB 30 mg Plus ABC/3TC (Induction Period)
Log10 copies per milliliterCAB 30 mg+ABC/3TC QD (Induction Period)
Week -20, n=3094.43 ± 0.672
Week -16, n=3041.71 ± 0.229
Week -12, n=3021.62 ± 0.108
Week -8, n=2991.63 ± 0.281
Week -4, n=2941.61 ± 0.080
Day 1, n=2911.60 ± 0.070
SecondaryChange From Baseline in Plasma HIV-1 RNA, for Oral Dose of CAB 30 mg Plus ABC/3TC (Induction Period)

Plasma samples for quantitative HIV-1 RNA were collected at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as: HIV-1 RNA(log 10) at post-baseline visit minus HIV-1 RNA(log 10) at Baseline.

Time frame:
Baseline (Week -20) and Week -16, Week -12, Week -8, Week -4, Day 1
Reported as:
Mean · Log10 copies per milliliter
Change From Baseline in Plasma HIV-1 RNA, for Oral Dose of CAB 30 mg Plus ABC/3TC (Induction Period)
Log10 copies per milliliterCAB 30 mg+ABC/3TC QD (Induction Period)
Week -16, n=304-2.72 ± 0.572
Week -12, n=302-2.80 ± 0.640
Week -8, n=299-2.79 ± 0.665
Week -4, n=294-2.81 ± 0.647
Day 1, n=291-2.82 ± 0.645
SecondaryAbsolute Values of Cluster of Differentiation 4+ (CD4+), for Oral Dose of CAB 30 mg Plus ABC/3TC (Induction Period)

Blood samples were collected at specified time points to assess CD4+ using flow cytometry. Mean and standard deviation values for CD4+ are presented.

Time frame:
Week -20, Week -16, Week -12, Week -4, Day 1
Reported as:
Mean · Cells per cubic millimeter
Absolute Values of Cluster of Differentiation 4+ (CD4+), for Oral Dose of CAB 30 mg Plus ABC/3TC (Induction Period)
Cells per cubic millimeterCAB 30 mg+ABC/3TC QD (Induction Period)
Week -20, n=309498.9 ± 180.67
Week -16, n=304630.5 ± 235.09
Week -12, n=300664.2 ± 256.57
Week -4, n=292702.3 ± 269.60
Day 1, n=291690.9 ± 261.63
SecondaryChange From Baseline in CD4+, for Oral Dose of CAB 30 mg Plus ABC/3TC (Induction Period)

Blood samples were collected at specified time points to assess CD4+. It was evaluated by flow cytometry. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.

Time frame:
Baseline (Week -20) and Week -16, Week -12, Week -4, Day 1
Reported as:
Mean · Cells per cubic millimeter
Change From Baseline in CD4+, for Oral Dose of CAB 30 mg Plus ABC/3TC (Induction Period)
Cells per cubic millimeterCAB 30 mg+ABC/3TC QD (Induction Period)
Week -16, n=304131.7 ± 172.69
Week -12, n=300164.5 ± 174.61
Week -4, n=292201.5 ± 195.53
Day 1, n=291188.7 ± 186.69
SecondaryNumber of Participants With AEs by Their Severity Grades, for Oral Dose of CAB 30 mg Plus ABC/3TC (Induction Period)

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Adverse events were evaluated by the investigator and graded according to the DAIDS toxicity grading, where Grade 1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening. The higher the grade, the more severe the symptoms. Number of participants with adverse events by maximum grade have been presented.

Time frame:
Up to 20 Weeks
Reported as:
Count of participants · Participants
Number of Participants With AEs by Their Severity Grades, for Oral Dose of CAB 30 mg Plus ABC/3TC (Induction Period)
ParticipantsCAB 30 mg+ABC/3TC QD (Induction Period)
Maximum toxicity Grade 127
Maximum toxicity Grade 215
Maximum toxicity Grade 32
Maximum toxicity Grade 41
SecondaryNumber of Participants With Maximum Post-Baseline Emergent Toxicities for Hematology Parameters, for Oral Dose of CAB 30 mg Plus ABC/3TC (Induction Period)

Hematology parameters hemoglobin, platelet count, total neutrophils and white blood cell count were evaluated. Laboratory toxicities were graded according to DAIDS grading criteria, where Grade 1-mild, Grade 2-moderate, Grade 3-severe, Grade 4-potentially life-threatening. Number of participants with any time post-baseline maximum emergent toxicities in any of the hematology parameters have been presented.

Time frame:
Up to Week 20
Reported as:
Count of participants · Participants
Number of Participants With Maximum Post-Baseline Emergent Toxicities for Hematology Parameters, for Oral Dose of CAB 30 mg Plus ABC/3TC (Induction Period)
ParticipantsCAB 30 mg+ABC/3TC QD (Induction Period)
Maximum toxicity Grade 126
Maximum toxicity Grade 24
Maximum toxicity Grade 31
Maximum toxicity Grade 43
SecondaryNumber of Participants With Maximum Post-Baseline Emergent Toxicities for Clinical Chemistry Parameters, for Oral Dose of CAB 30 mg Plus ABC/3TC (Induction Period)

Clinical chemistry parameters AST, ALT, ALP, CO2/HCO3, cholesterol, CK, glucose, LDL cholesterol, lipase, potassium, and sodium, total TBIL and triglycerides were evaluated. Laboratory toxicities were graded according to DAIDS grading criteria, where Grade 1-mild, Grade 2-moderate, Grade 3-severe, Grade 4-potentially life-threatening. Number of participants with any time post-baseline maximum emergent toxicities in any of the chemistry parameters have been presented.

Time frame:
Up to 20 weeks
Reported as:
Count of participants · Participants
Number of Participants With Maximum Post-Baseline Emergent Toxicities for Clinical Chemistry Parameters, for Oral Dose of CAB 30 mg Plus ABC/3TC (Induction Period)
ParticipantsCAB 30 mg+ABC/3TC QD (Induction Period)
Maximum toxicity Grade 1130
Maximum toxicity Grade 250
Maximum toxicity Grade 316
Maximum toxicity Grade 45
SecondaryChange From Baseline in Clinical Chemistry Parameters: ALT, ALP, AST and CK (Induction Period)

Blood samples were collected for the analysis of clinical chemistry parameters including ALT, ALP, AST and CK at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.

Time frame:
Baseline (Week -20) and Week -16, Week -12, Week -8, Week -4, Day 1
Reported as:
Mean · International Units per Liter (IU/L)
Change From Baseline in Clinical Chemistry Parameters: ALT, ALP, AST and CK (Induction Period)
International Units per Liter (IU/L)CAB 30 mg+ABC/3TC QD (Induction Period)
ALT, Week -16, n=3060.4 ± 33.1
ALT, Week -12, n=301-1.3 ± 14.1
ALT, Week -8, n=297-0.5 ± 16.6
ALT, Week -4, n=2921.5 ± 50.3
ALT, Day 1, n=287-1.2 ± 18.0
ALP, Week -16, n=306-2.1 ± 12.0
ALP, Week -12, n=301-2.6 ± 11.0
ALP, Week -8, n=297-1.2 ± 13.0
ALP, Week -4, n=2920.1 ± 15.4
ALP, Day 1, n=2870.1 ± 14.1
AST, Week -16, n=3060.3 ± 33.4
AST, Week -12, n=301-2.2 ± 13.1
AST, Week -8, n=296-1.7 ± 15.8
AST, Week -4, n=292-0.0 ± 30.9
AST, Day 1, n=286-1.0 ± 25.9
CK, Week -16, n=30619.0 ± 345.6
CK, Week -12, n=30129.4 ± 485.4
CK, Week -8, n=29726.3 ± 529.6
CK, Week -4, n=29233.2 ± 434.2
CK, Day 1, n=28769.9 ± 1164.7
SecondaryChange From Baseline in Clinical Chemistry Parameter: Albumin (Induction Period)

Blood samples were collected for the analysis of clinical chemistry parameter: Albumin at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.

Time frame:
Baseline (Week -20) and Week -16, Week -12, Week -8, Week -4, Day 1
Reported as:
Mean · Grams per Liter (G/L)
Change From Baseline in Clinical Chemistry Parameter: Albumin (Induction Period)
Grams per Liter (G/L)CAB 30 mg+ABC/3TC QD (Induction Period)
Week -16, n=3060.2 ± 2.3
Week -12, n=3010.7 ± 2.3
Week -8, n=2971.4 ± 2.6
Week -4, n=2921.7 ± 2.6
Day 1, n=2871.9 ± 2.8
SecondaryChange From Baseline in Clinical Chemistry Parameters: Total Bilirubin and Creatinine (Induction Period)

Blood samples were collected for the analysis of clinical chemistry parameters including total Bilirubin and Creatinine at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.

Time frame:
Baseline (Week -20) and Week -16, Week -12, Week -8, Week -4, Day 1
Reported as:
Mean · Micromoles per Liter (umol/L)
Change From Baseline in Clinical Chemistry Parameters: Total Bilirubin and Creatinine (Induction Period)
Micromoles per Liter (umol/L)CAB 30 mg+ABC/3TC QD (Induction Period)
Total Bilirubin, Week -16, n=305-0.6 ± 4.5
Total Bilirubin, Week -12, n=301-0.9 ± 4.0
Total Bilirubin, Week -8, n=297-1.0 ± 4.1
Total Bilirubin, Week -4, n=292-0.5 ± 4.1
Total Bilirubin, Day 1, n=287-0.3 ± 4.0
Creatinine, Week -16, n=3062.6 ± 7.6
Creatinine, Week -12, n=3011.5 ± 7.8
Creatinine, Week -8, n=2971.6 ± 7.8
Creatinine, Week -4, n=2923.5 ± 8.7
Creatinine, Day 1, n=2874.6 ± 9.1
SecondaryChange From Baseline in Clinical Chemistry Parameters: CO2, Chloride, Cholesterol, Glucose, Potassium, Sodium, Triglyceride and Urea (Induction Period)

Blood samples were collected for the analysis of clinical chemistry parameters including total CO2, chloride, cholesterol, glucose, potassium, sodium, triglyceride and urea at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.

Time frame:
Baseline (Week -20) and Week -16, Week -12, Week -8, Week -4, Day 1
Reported as:
Mean · Millimoles per Liter (mmol/L)
Change From Baseline in Clinical Chemistry Parameters: CO2, Chloride, Cholesterol, Glucose, Potassium, Sodium, Triglyceride and Urea (Induction Period)
Millimoles per Liter (mmol/L)CAB 30 mg+ABC/3TC QD (Induction Period)
CO2, Week -16, n=3060.2 ± 2.4
CO2, Week -12, n=3010.3 ± 2.3
CO2, Week -8, n=2960.4 ± 2.3
CO2, Week -4, n=2920.1 ± 2.3
CO2, Day 1, n=286-0.8 ± 2.6
Chloride, Week -16, n=3060.2 ± 2.3
Chloride, Week -12, n=3010.5 ± 2.2
Chloride, Week -8, n=2970.6 ± 2.3
Chloride, Week -4, n=2920.2 ± 2.3
Chloride, Day 1, n=2870.2 ± 2.3
Cholesterol, Week -16, n=2550.21 ± 0.6
Cholesterol, Week -12, n=2360.19 ± 0.5
Cholesterol, Week -8, n=2350.27 ± 0.5
Cholesterol, Week -4, n=2820.34 ± 0.5
Cholesterol, Day 1, n=2850.34 ± 0.6
Glucose, Week -16, n=2550.07 ± 0.7
Glucose, Week -12, n=2360.16 ± 0.7
Glucose, Week -8, n=2350.08 ± 0.7
Glucose, Week -4, n=2810.06 ± 0.7
Glucose, Day 1, n=282-0.01 ± 0.7
Potassium, Week -16, n=306-0.05 ± 0.2
Potassium, Week -12, n=301-0.03 ± 0.3
Potassium, Week -8, n=2960.03 ± 0.3
Potassium, Week -4, n=2920.03 ± 0.3
Potassium, Day 1, n=2860.03 ± 0.3
Sodium, Week -16, n=306-0.1 ± 1.8
Sodium, Week -12, n=3010.1 ± 1.8
Sodium, Week -8, n=2970.2 ± 1.9
Sodium, Week -4, n=2920.4 ± 2.0
Sodium, Day 1, n=2870.3 ± 1.9
Triglyceride, Week -16, n=3-0.69 ± 0.1
Triglyceride, Week -12, n=2-0.37 ± 0.1
Triglyceride, Week -8, n=20.29 ± 0.4
Triglyceride, Week -4, n=2780.20 ± 0.9
Triglyceride, Day 1, n=278-0.00 ± 0.7
Urea, Week -16, n=306-0.06 ± 1.2
Urea, Week -12, n=301-0.08 ± 1.2
Urea, Week -8, n=297-0.09 ± 1.1
Urea, Week -4, n=292-0.12 ± 1.3
Urea, Day 1, n=2870.00 ± 1.2
SecondaryChange From Baseline in Clinical Chemistry Parameter: Lipase (Induction Period)

Blood samples were collected for the analysis of clinical chemistry parameter: Lipase at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.

Time frame:
Baseline (Week -20) and Week -16, Week -12, Week -8, Week -4, Day 1
Reported as:
Mean · Units per Liter (U/L)
Change From Baseline in Clinical Chemistry Parameter: Lipase (Induction Period)
Units per Liter (U/L)CAB 30 mg+ABC/3TC QD (Induction Period)
Week -16, n=3063.3 ± 20.0
Week -12, n=3010.8 ± 15.3
Week -8, n=2972.8 ± 24.3
Week -4, n=2922.1 ± 23.8
Day 1, n=288-1.2 ± 17.7
SecondaryChange From Baseline in Hematology Parameters: Basophil, Eosinophils, Lymphocytes, Total Neutrophils, Monocytes, Platelets Count and White Blood Cells (WBC) Count (Induction Period)

Blood samples were collected for the analysis of hematology parameters: Basophil, Eosinophils, Lymphocytes, Total Neutrophils, Monocytes, Platelets count and WBC at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.

Time frame:
Baseline (Week -20) and Week -16, Week -12, Week -8, Week -4, Day 1
Reported as:
Mean · Giga cells per Liter
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Lymphocytes, Total Neutrophils, Monocytes, Platelets Count and White Blood Cells (WBC) Count (Induction Period)
Giga cells per LiterCAB 30 mg+ABC/3TC QD (Induction Period)
Basophils, Week -16, n=3030.00 ± 0.016
Basophils, Week -12, n=2980.00 ± 0.019
Basophils, Week -8, n=2970.00 ± 0.015
Basophils, Week -4, n=2900.00 ± 0.016
Basophils, Day 1, n=2900.00 ± 0.019
Eosinophils, Week -16, n=3030.01 ± 0.131
Eosinophils, Week -12, n=2980.01 ± 0.123
Eosinophils, Week -8, n=2970.02 ± 0.127
Eosinophils, Week -4, n=2900.02 ± 0.136
Eosinophils, Day 1, n=2900.03 ± 0.161
Lymphocytes, Week -16, n=3030.24 ± 0.541
Lymphocytes, Week -12, n=2980.28 ± 0.573
Lymphocytes, Week -8, n=2970.30 ± 0.541
Lymphocytes, Week -4, n=2900.30 ± 0.574
Lymphocytes, Day 1, n=2900.14 ± 0.565
Monocytes, Week -16, n=303-0.00 ± 0.129
Monocytes, Week -12, n=2980.00 ± 0.139
Monocytes, Week -8, n=297-0.00 ± 0.135
Monocytes, Week -4, n=290-0.00 ± 0.132
Monocytes, Day 1, n=2900.00 ± 0.143
Platelet count, Week -16, n=30214.4 ± 31.56
Platelet count, Week -12, n=30018.2 ± 32.53
Platelet count, Week -8, n=29721.1 ± 37.00
Platelet count, Week -4, n=29023.0 ± 35.02
Platelet count, Day 1, n=29022.2 ± 35.32
Total Neutrophils, Week -16, n=3030.04 ± 1.185
Total Neutrophils, Week -12, n=2980.22 ± 1.391
Total Neutrophils, Week -8, n=2970.20 ± 1.286
Total Neutrophils, Week -4, n=2900.31 ± 1.429
Total Neutrophils, Day 1, n=2900.38 ± 1.515
WBC, Week -16, n=3030.31 ± 1.318
WBC, Week -12, n=2980.52 ± 1.522
WBC, Week -8, n=2970.54 ± 1.460
WBC, Week -4, n=2900.64 ± 1.594
WBC, Day 1, n=2900.57 ± 1.713
SecondaryChange From Baseline in Hematology Parameter: Hematocrit (Induction Period)

Blood samples were collected for the analysis of hematology parameter: Hematocrit at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.

Time frame:
Baseline (Week -20) and Week -16, Week -12, Week -8, Week -4, Day 1
Reported as:
Mean · Proportion of red blood cells in blood
Change From Baseline in Hematology Parameter: Hematocrit (Induction Period)
Proportion of red blood cells in bloodCAB 30 mg+ABC/3TC QD (Induction Period)
Week -16, n=3040.00 ± 0.022
Week -12, n=3020.00 ± 0.023
Week -8, n=2980.00 ± 0.024
Week -4, n=2900.00 ± 0.025
Day 1, n=2900.00 ± 0.025
SecondaryChange From Baseline in Hematology Parameter: Hemoglobin (Induction Period)

Blood samples were collected for the analysis of hematology parameter: Hemoglobin at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.

Time frame:
Baseline (Week -20) and Week -16, Week -12, Week -8, Week -4, Day 1
Reported as:
Mean · Grams per Liter
Change From Baseline in Hematology Parameter: Hemoglobin (Induction Period)
Grams per LiterCAB 30 mg+ABC/3TC QD (Induction Period)
Week -16, n=3040.8 ± 6.94
Week -12, n=3022.0 ± 7.07
Week -8, n=2982.5 ± 7.42
Week -4, n=2903.3 ± 7.95
Day 1, n=2903.1 ± 7.96
SecondaryChange From Baseline in Hematology Parameter: Mean Corpuscle Volume (Induction Period)

Blood samples were collected for the analysis of hematology parameter: Mean Corpuscle Volume at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.

Time frame:
Baseline (Week -20) and Week -16, Week -12, Week -8, Week -4, Day 1
Reported as:
Mean · Femtoliters
Change From Baseline in Hematology Parameter: Mean Corpuscle Volume (Induction Period)
FemtolitersCAB 30 mg+ABC/3TC QD (Induction Period)
Week -16, n=3041.0 ± 1.52
Week -12, n=3022.1 ± 1.90
Week -8, n=2983.1 ± 2.49
Week -4, n=2904.0 ± 2.47
Day 1, n=2904.4 ± 2.57
SecondaryChange From Baseline in Hematology Parameter: Red Blood Cell Count (Induction Period)

Blood samples were collected for the analysis of hematology parameter: Red Blood Cell count at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.

Time frame:
Baseline (Week -20) and Week -16, Week -12, Week -8, Week -4, Day 1
Reported as:
Mean · 10^12 cells per Liter
Change From Baseline in Hematology Parameter: Red Blood Cell Count (Induction Period)
10^12 cells per LiterCAB 30 mg+ABC/3TC QD (Induction Period)
Week -16, n=304-0.05 ± 0.242
Week -12, n=302-0.07 ± 0.254
Week -8, n=298-0.10 ± 0.266
Week -4, n=290-0.10 ± 0.284
Day 1, n=290-0.14 ± 0.289
SecondaryPercentage of Participants With Plasma HIV-1 RNA Level <50 c/mL and <200 c/mL Over Week 96 (Maintenance Period)

Percentage of participants with HIV-1 RNA \<50 c/mL and \<200 c/mL was obtained using FDA Snapshot algorithm. The algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as well as participants who switch their concomitant ART prior to the visit of interest, as non-responders.

Time frame:
From Day 1 up to Week 96
Reported as:
Number · Percentage of participants
Percentage of Participants With Plasma HIV-1 RNA Level <50 c/mL and <200 c/mL Over Week 96 (Maintenance Period)
Percentage of participantsCAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period)CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period)CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period)
HIV-1 RNA<50 c/mL, Day 1959998
HIV-1 RNA<50 c/mL, Week 4979893
HIV-1 RNA<50 c/mL, Week 8989795
HIV-1 RNA<50 c/mL, Week 12969798
HIV-1 RNA<50 c/mL, Week 16979689
HIV-1 RNA<50 c/mL, Week 20979791
HIV-1 RNA<50 c/mL, Week 24969491
HIV-1 RNA<50 c/mL, Week 28909286
HIV-1 RNA<50 c/mL, Week 32959491
HIV-1 RNA<50 c/mL, Week 36959088
HIV-1 RNA<50 c/mL, Week 40929186
HIV-1 RNA<50 c/mL, Week 44939088
HIV-1 RNA<50 c/mL, Week 48929189
HIV-1 RNA<50 c/mL, Week 56949084
HIV-1 RNA<50 c/mL, Week 64959086
HIV-1 RNA<50 c/mL, Week 72959088
HIV-1 RNA<50 c/mL, Week 80958784
HIV-1 RNA<50 c/mL, Week 88958684
HIV-1 RNA<50 c/mL, Week 96948784
HIV-1 RNA<200 c/mL, Day 110010098
HIV-1 RNA<200 c/mL, Week 49910096
HIV-1 RNA<200 c/mL, Week 8999995
HIV-1 RNA<200 c/mL, Week 12979898
HIV-1 RNA<200 c/mL, Week 16989893
HIV-1 RNA<200 c/mL, Week 20989793
HIV-1 RNA<200 c/mL, Week 24979693
HIV-1 RNA<200 c/mL, Week 28949591
HIV-1 RNA<200 c/mL, Week 32979591
HIV-1 RNA<200 c/mL, Week 36979389
HIV-1 RNA<200 c/mL, Week 40979286
HIV-1 RNA<200 c/mL, Week 44959189
HIV-1 RNA<200 c/mL, Week 48979289
HIV-1 RNA<200 c/mL, Week 56969086
HIV-1 RNA<200 c/mL, Week 64969088
HIV-1 RNA<200 c/mL, Week 72969088
HIV-1 RNA<200 c/mL, Week 80968884
HIV-1 RNA<200 c/mL, Week 88968684
HIV-1 RNA<200 c/mL, Week 96968784
SecondaryNumber of Participants With Protocol Defined Virologic Failure at Week 32 and Week 48 (Maintenance Period)

Virologic failure was defined as any of the following: (1) Non-response as indicated by a less than a 1.0 log10 c/mL decrease in plasma HIV-1 RNA after 4 weeks of starting the Induction Period, which is subsequently confirmed, unless the plasma HIV-1 RNA is \< 400 c/mL; (2) Rebound as indicated by two consecutive plasma HIV-1 RNA levels \>=200 c/mL after prior suppression to \< 200 c/mL; (3) Rebound as indicated by two consecutive plasma HIV-1 RNA that are \> 0.5 log10 c/mL increase in plasma HIV-1 RNA from the nadir value on study, where the lowest HIV-1 RNA value is \>=200 c/mL.

Time frame:
At Week 32 and Week 48
Reported as:
Number · Participants
Number of Participants With Protocol Defined Virologic Failure at Week 32 and Week 48 (Maintenance Period)
ParticipantsCAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period)CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period)CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period)
Week 32101
Week 48201
SecondaryAbsolute Value of Plasma HIV-1 RNA at Week 32 and Week 96 (Maintenance Period)

Plasma samples for quantitative HIV-1 RNA analysis were collected at indicated time points during Maintenance Period. Log10 values for HIV-1 RNA have been presented. SD=0.000 is defined as following: if participants analyzed at a specific timepoint have resulted same values, then SD is considered equal with 0.000.

Time frame:
At Week 32 and Week 96
Reported as:
Mean · Log10 copies per milliliter
Absolute Value of Plasma HIV-1 RNA at Week 32 and Week 96 (Maintenance Period)
Log10 copies per milliliterCAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period)CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period)CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period)
Week 321.60 ± 0.0441.59 ± 0.0251.61 ± 0.112
Week 961.60 ± 0.0561.59 ± 0.0001.59 ± 0.000
SecondaryChange From Baseline in Plasma HIV-1 RNA at Week 32 and Week 96 (Maintenance Period)

Plasma samples for quantitative HIV-1 RNA analysis were collected at indicated time points during Maintenance Period. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as: HIV-1 RNA(log 10) at post-baseline visit minus HIV-1 RNA(log 10) at Baseline.

Time frame:
At Week 32 and Week 96 (compared with Baseline [Week -20])
Reported as:
Mean · Log10 copies per milliliter
Change From Baseline in Plasma HIV-1 RNA at Week 32 and Week 96 (Maintenance Period)
Log10 copies per milliliterCAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period)CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period)CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period)
Week 32-2.78 ± 0.610-2.88 ± 0.709-2.73 ± 0.561
Week 96-2.77 ± 0.602-2.89 ± 0.713-2.77 ± 0.582
SecondaryAbsolute Value of CD4+ at Week 32 and Week 96 (Maintenance Period)

Blood samples were collected at specified time points to assess CD4+. It was evaluated by flow cytometry.

Time frame:
At Week 32 and Week 96
Reported as:
Mean · Cells per cubic millimeter
Absolute Value of CD4+ at Week 32 and Week 96 (Maintenance Period)
Cells per cubic millimeterCAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period)CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period)CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period)
Week 32752.3 ± 318.02761.3 ± 293.07891.3 ± 273.32
Week 96748.6 ± 253.41750.0 ± 271.11906.8 ± 288.77
SecondaryChange From Baseline in CD4+ at Week 32 and Week 96 (Maintenance Period)

Blood samples were collected at specified time points to assess CD4+. It was evaluated by flow cytometry. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as post-baseline value minus Baseline value.

Time frame:
At Week 32 and Week 96 (compared with Baseline [Week -20])
Reported as:
Mean · Cells per cubic millimeter
Change From Baseline in CD4+ at Week 32 and Week 96 (Maintenance Period)
Cells per cubic millimeterCAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period)CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period)CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period)
Week 32264.4 ± 247.84263.7 ± 217.74346.1 ± 219.59
Week 96257.5 ± 192.25270.6 ± 210.99369.9 ± 226.60
SecondaryNumber of Participants With HIV-1 Disease Progression Over Week 32 and Week 96 (Maintenance Period)

HIV-associated conditions were recorded during the study and was assessed according to the Centers for Disease Control and Prevention (CDC) Classification System for HIV Infection in Adults. The clinical categories of HIV infection as per CDC system are class A=Asymptomatic HIV infection or lymphadenopathy or acute HIV infection; class B=symptomatic non-acquired immunodeficiency syndrome (AIDS) conditions and class C=AIDS indicator conditions. Number of participants experiencing disease progression is presented, where disease progression is defined as the progression from Baseline HIV disease status as follows: CDC class A at Baseline to CDC class C event; CDC Class B at Baseline to CDC Class C event; CDC Class C at Baseline to new CDC Class C event; and CDC class A, B or C at Baseline to death.

Time frame:
At Week 32 and Week 96
Reported as:
Count of participants · Participants
Number of Participants With HIV-1 Disease Progression Over Week 32 and Week 96 (Maintenance Period)
ParticipantsCAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period)CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period)CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period)
From CDC Stage 1 to CDC Stage 3 Event, Week 32100
From CDC Stage 2 to CDC Stage 3 Event, Week 32000
From CDC Stage 3 to New CDC Stage 3 Event, Week 32000
From CDC Stage 1, 2 or 3 to Death, Week 32010
From CDC Stage 1 to CDC Stage 3 Event, Week 96400
From CDC Stage 2 to CDC Stage 3 Event, Week 96000
From CDC Stage 3 to New CDC Stage 3 Event, Week 96000
From CDC Stage 1, 2 or 3 to Death, Week 96010
SecondaryNumber of Participants With AEs by Their Severity Grades Over Week 32 (Maintenance Period)

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Adverse events were evaluated by the investigator and graded according to the DAIDS toxicity grading, where Grade 1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening). The higher the grade, the more severe the symptoms. Number of participants with adverse events by maximum grade have been presented.

Time frame:
Up to Week 32
Reported as:
Count of participants · Participants
Number of Participants With AEs by Their Severity Grades Over Week 32 (Maintenance Period)
ParticipantsCAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period)CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period)CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period)
Grade 1352923
Grade 2656922
Grade 314131
Grade 4120
SecondaryNumber of Participants With AEs by Their Severity Grades Over Week 96 (Maintenance Period)

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Adverse events were evaluated by the investigator and graded according to the DAIDS toxicity grading, where Grade 1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening). The higher the grade, the more severe the symptoms. Number of participants with adverse events by maximum grade have been presented.

Time frame:
Up to Week 96
Reported as:
Count of participants · Participants
Number of Participants With AEs by Their Severity Grades Over Week 96 (Maintenance Period)
ParticipantsCAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period)CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period)CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period)
Grade 1232124
Grade 2717426
Grade 319184
Grade 4220
SecondaryChange From Baseline in Clinical Chemistry Parameters: ALT, ALP, AST and CK at Week 32 and Week 96 (Maintenance Period)

Blood samples were collected for the analysis of clinical chemistry parameters including ALT, ALP, AST and CK at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.

Time frame:
At Week 32 and Week 96 (compared with Baseline [Week -20])
Reported as:
Mean · International Units per Liter
Change From Baseline in Clinical Chemistry Parameters: ALT, ALP, AST and CK at Week 32 and Week 96 (Maintenance Period)
International Units per LiterCAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period)CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period)CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period)
ALT, Week 32-2.4 ± 13.4-2.7 ± 13.5-5.0 ± 19.5
ALP, Week 32-1.2 ± 14.6-3.8 ± 15.0-1.3 ± 11.6
AST, Week 32-2.8 ± 12.5-2.2 ± 14.5-8.3 ± 30.6
CK, Week 3251.4 ± 651.093.4 ± 446.938.8 ± 394.9
ALT, Week 961.8 ± 19.19-2.2 ± 14.42-2.7 ± 22.17
ALP, Week 96-3.1 ± 15.59-3.4 ± 15.64-2.8 ± 12.34
AST, Week 96-1.0 ± 15.45-4.0 ± 9.31-8.8 ± 32.57
CK, Week 9621.1 ± 490.0013.7 ± 153.92-13.9 ± 227.98
SecondaryChange From Baseline in Clinical Chemistry Parameter: Albumin at Week 32 and Week 96 (Maintenance Period)

Blood samples were collected for the analysis of clinical chemistry parameters including Albumin at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.

Time frame:
At Week 32 and Week 96 (compared with Baseline [Week -20])
Reported as:
Mean · Grams per Liter
Change From Baseline in Clinical Chemistry Parameter: Albumin at Week 32 and Week 96 (Maintenance Period)
Grams per LiterCAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period)CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period)CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period)
Week 321.4 ± 3.00.9 ± 2.91.1 ± 2.8
Week 961.0 ± 2.760.9 ± 2.870.2 ± 2.61
SecondaryChange From Baseline in Clinical Chemistry Parameters: Total Bilirubin and Creatinine at Week 32 and Week 96 (Maintenance Period)

Blood samples were collected for the analysis of clinical chemistry parameters including Total Bilirubin and Creatinine at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.

Time frame:
At Week 32 and Week 96 (compared with Baseline [Week -20])
Reported as:
Mean · Micromoles per Liter
Change From Baseline in Clinical Chemistry Parameters: Total Bilirubin and Creatinine at Week 32 and Week 96 (Maintenance Period)
Micromoles per LiterCAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period)CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period)CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period)
Total Bilirubin, Week 320.8 ± 4.40.4 ± 3.6-0.6 ± 4.4
Creatinine, Week 322.7 ± 8.53.8 ± 8.72.7 ± 6.1
Total Bilirubin, Week 960.0 ± 3.78-0.3 ± 4.11-1.1 ± 4.25
Creatinine, Week 963.11 ± 8.5154.27 ± 8.7304.42 ± 6.105
SecondaryChange From Baseline in Clinical Chemistry Parameters: Total CO2, Chloride, Cholesterol, Glucose, Potassium, Sodium, Triglyceride and Urea at Week 32 and Week 96 (Maintenance Period)

Blood samples were collected for the analysis of clinical chemistry parameters including total CO2, chloride, cholesterol, glucose, potassium, sodium, triglyceride and urea at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.

Time frame:
At Week 32 and Week 96 (compared with Baseline [Week -20])
Reported as:
Mean · Millimoles per Liter
Change From Baseline in Clinical Chemistry Parameters: Total CO2, Chloride, Cholesterol, Glucose, Potassium, Sodium, Triglyceride and Urea at Week 32 and Week 96 (Maintenance Period)
Millimoles per LiterCAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period)CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period)CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period)
Total CO2, Week 32-0.8 ± 2.1-1.5 ± 2.4-1.1 ± 2.4
Chloride, Week 32-0.2 ± 2.2-0.3 ± 2.40.1 ± 2.1
Cholesterol, Week 320.37 ± 0.60.47 ± 0.70.25 ± 0.5
Glucose, Week 320.13 ± 1.00.03 ± 0.7-0.05 ± 0.6
Potassium, Week 320.01 ± 0.3-0.05 ± 0.3-0.04 ± 0.2
Sodium, Week 320.4 ± 2.0-0.1 ± 1.80.0 ± 1.7
Triglycerides, Week 320.08 ± 0.9-0.00 ± 1.70.06 ± 0.7
Urea, Week 320.15 ± 1.30.23 ± 1.4-0.01 ± 1.4
Total CO2, Week 96-0.8 ± 2.88-1.1 ± 2.64-0.1 ± 2.47
Chloride, Week 96-0.1 ± 2.32-0.4 ± 2.530.3 ± 2.12
Cholesterol, Week 960.554 ± 0.67240.731 ± 0.73800.348 ± 0.6490
Glucose, Week 960.12 ± 0.7290.11 ± 0.6670.02 ± 0.745
Potassium, Week 960.11 ± 0.378-0.04 ± 0.408-0.03 ± 0.314
Sodium, Week 96-0.1 ± 1.85-0.4 ± 2.07-0.4 ± 1.96
Triglycerides, Week 960.084 ± 0.90000.080 ± 1.49640.197 ± 0.4972
Urea, Week 960.09 ± 1.393-0.01 ± 1.2300.12 ± 1.461
SecondaryChange From Baseline in Clinical Chemistry Parameter: Lipase at Week 32 and Week 96 (Maintenance Period)

Blood samples were collected for the analysis of clinical chemistry parameters including Lipase at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.

Time frame:
At Week 32 and Week 96 (compared with Baseline [Week -20])
Reported as:
Mean · Units per Liter
Change From Baseline in Clinical Chemistry Parameter: Lipase at Week 32 and Week 96 (Maintenance Period)
Units per LiterCAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period)CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period)CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period)
Week 32-1.2 ± 33.2-4.4 ± 15.4-3.9 ± 14.7
Week 963.5 ± 22.00-0.8 ± 14.73-2.3 ± 14.21
SecondaryChange From Baseline in Hematology Parameters: Basophil, Eosinophils, Lymphocytes, Total Neutrophils, Monocytes, Platelet Count and WBC Count at Week 32 and Week 96 (Maintenance Period)

Blood samples were collected for the analysis of hematology parameters including Basophil, Eosinophils, Lymphocytes, Total Neutrophils, Monocytes, Platelet count and WBC count at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.

Time frame:
At Week 32 and Week 96 (compared with Baseline [Week -20])
Reported as:
Mean · 10^9 cells per Liter
Change From Baseline in Hematology Parameters: Basophil, Eosinophils, Lymphocytes, Total Neutrophils, Monocytes, Platelet Count and WBC Count at Week 32 and Week 96 (Maintenance Period)
10^9 cells per LiterCAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period)CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period)CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period)
Basophils, Week 320.00 ± 0.012-0.00 ± 0.0220.00 ± 0.010
Eosinophils, Week 320.01 ± 0.1460.23 ± 1.985-0.01 ± 0.143
Lymphocytes, Week 320.34 ± 0.6610.26 ± 0.6940.48 ± 0.635
Monocytes, Week 32-0.02 ± 0.152-0.03 ± 0.144-0.00 ± 0.144
Platelet count, Week 3218.7 ± 38.2820.6 ± 44.9311.6 ± 33.33
Total Neutrophils, Week 320.59 ± 1.5050.34 ± 1.4890.94 ± 1.365
WBC count, Week 320.93 ± 1.6700.81 ± 2.8811.41 ± 1.529
Basophils, Week 960.004 ± 0.01390.000 ± 0.02040.006 ± 0.0157
Eosinophils, Week 960.015 ± 0.14610.021 ± 0.1013-0.013 ± 0.1528
Lymphocytes, Week 960.325 ± 0.63560.290 ± 0.67930.534 ± 0.5408
Monocytes, Week 96-0.009 ± 0.1685-0.014 ± 0.1781-0.005 ± 0.1443
Platelet count, Week 9621.9 ± 40.0721.1 ± 41.4915.3 ± 39.28
Total Neutrophils, Week 960.381 ± 1.30600.515 ± 1.62000.783 ± 1.0747
WBC count, Week 960.72 ± 1.5450.82 ± 1.7861.31 ± 1.144
SecondaryChange From Baseline in Hematology Parameter: Hematocrit at Week 32 and Week 96 (Maintenance Period)

Blood samples were collected for the analysis of hematology parameters including Hematocrit at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.

Time frame:
At Week 32 and Week 96 (compared with Baseline [Week -20])
Reported as:
Mean · Proportion of red blood cells in blood
Change From Baseline in Hematology Parameter: Hematocrit at Week 32 and Week 96 (Maintenance Period)
Proportion of red blood cells in bloodCAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period)CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period)CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period)
Week 320.01 ± 0.0260.01 ± 0.0270.01 ± 0.027
Week 960.0114 ± 0.028800.0134 ± 0.031250.0124 ± 0.02748
SecondaryChange From Baseline in Hematology Parameter: Hemoglobin at Week 32 and Week 96 (Maintenance Period)

Blood samples were collected for the analysis of hematology parameters including Hemoglobin at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.

Time frame:
At Week 32 and Week 96 (compared with Baseline [Week -20])
Reported as:
Mean · Grams per Liter
Change From Baseline in Hematology Parameter: Hemoglobin at Week 32 and Week 96 (Maintenance Period)
Grams per LiterCAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period)CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period)CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period)
Week 322.0 ± 8.560.8 ± 8.451.7 ± 8.38
Week 963.9 ± 8.954.3 ± 9.924.1 ± 8.11
SecondaryChange From Baseline in Hematology Parameter: Mean Corpuscle Volume at Week 32 and Week 96 (Maintenance Period)

Blood samples were collected for the analysis of hematology parameters including Mean Corpuscle Volume at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.

Time frame:
At Week 32 and Week 96 (compared with Baseline [Week -20])
Reported as:
Mean · Femtoliters
Change From Baseline in Hematology Parameter: Mean Corpuscle Volume at Week 32 and Week 96 (Maintenance Period)
FemtolitersCAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period)CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period)CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period)
Week 322.5 ± 1.972.3 ± 2.547.1 ± 2.88
Week 960.1 ± 2.990.3 ± 2.545.3 ± 3.14
SecondaryChange From Baseline in Hematology Parameter: Red Blood Cell Count at Week 32 and Week 96 (Maintenance Period)

Blood samples were collected for the analysis of hematology parameters including Red Blood Cell count at indicated time points. Baseline (Week -20) refers to the last available value up to and including the date of first induction period dosing with CAB 30 mg plus ABC/3TC. Change from Baseline was defined as value at post-baseline visit minus value at Baseline.

Time frame:
At Week 32 and Week 96 (compared with Baseline [Week -20])
Reported as:
Mean · 10^12 cells per Liter
Change From Baseline in Hematology Parameter: Red Blood Cell Count at Week 32 and Week 96 (Maintenance Period)
10^12 cells per LiterCAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period)CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period)CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period)
Week 320.03 ± 0.2860.02 ± 0.278-0.20 ± 0.296
Week 960.12 ± 0.2940.14 ± 0.310-0.13 ± 0.293
SecondaryAverage Initial Concentration (C0) and Maximum Plasma Concentration (Cmax) of CAB LA (Q4W IM and Q8W IM Dosing) (Maintenance Period)

Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of CAB LA. The PK Concentration Population included all participants who received CAB LA and/or RPV LA and underwent PK sampling during the study, and provided available CAB LA and/or RPV LA plasma concentration data.

Time frame:
Up to Week 32
Reported as:
Geometric mean · Micrograms per milliliter
Average Initial Concentration (C0) and Maximum Plasma Concentration (Cmax) of CAB LA (Q4W IM and Q8W IM Dosing) (Maintenance Period)
Micrograms per milliliterCAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period)CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period)
C01.43 ± 542.35 ± 32
Cmax3.55 ± 563.50 ± 39
SecondaryAverage Initial Concentration (C0) and Cmax of RPV LA (Q4W IM and Q8W IM Dosing) (Maintenance Period)

Blood samples were collected at indicated time points for PK analysis of RPV LA. C0 and Cmax of RPV LA (Q4W IM and Q8W IM dosing) was evaluated.

Time frame:
Up to Week 32
Reported as:
Geometric mean · Nanograms per milliliter
Average Initial Concentration (C0) and Cmax of RPV LA (Q4W IM and Q8W IM Dosing) (Maintenance Period)
Nanograms per milliliterCAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period)CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period)
C049.3 ± 4177.2 ± 35
Cmax104 ± 47111 ± 40
SecondaryTrough Concentration (Ctrough) of CAB LA (Q8W IM Dosing) Used for Assessment of Steady State (Maintenance Period)

Blood samples were collected at indicated time points for PK analysis of CAB LA. Ctrough is the lowest concentration reached by a drug before the next dose is administered. Ctrough for CAB LA (Q8W IM dosing) which were considered for the assessment of steady state are presented.

Time frame:
Pre-dose on Weeks 16, 24 and 32
Reported as:
Mean · Micrograms per milliliter
Trough Concentration (Ctrough) of CAB LA (Q8W IM Dosing) Used for Assessment of Steady State (Maintenance Period)
Micrograms per milliliterCAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period)
Week 16, n=871.6902 ± 0.80471
Week 24, n=861.6051 ± 0.78254
Week 32, n=841.5330 ± 0.70822
SecondaryCtrough of CAB LA (Q4W IM Dosing) Used for Assessment of Steady State (Maintenance Period)

Blood samples were collected at indicated time points for PK analysis of CAB LA. Ctrough is the lowest concentration reached by a drug before the next dose is administered. Ctrough for CAB LA (Q4W IM dosing) which were considered for the assessment of steady state are presented.

Time frame:
Pre-dose on Weeks 16, 20, 24, 28 and 32
Reported as:
Mean · Micrograms per milliliter
Ctrough of CAB LA (Q4W IM Dosing) Used for Assessment of Steady State (Maintenance Period)
Micrograms per milliliterCAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period)
Week 16, n=782.2703 ± 0.92102
Week 20, n=772.3861 ± 0.76176
Week 24, n=782.6342 ± 1.29093
Week 28, n=822.4365 ± 0.86420
Week 32, n=852.4715 ± 0.89893
SecondaryCtrough of RPV LA (Q8W IM Dosing) Used for Assessment of Steady State (Maintenance Period)

Blood samples were collected at indicated time points for PK analysis of RPV LA. Ctrough is the lowest concentration reached by a drug before the next dose is administered. Ctrough for RPV LA (Q8W IM dosing) which were considered for the assessment of steady state are presented.

Time frame:
Pre-dose on Weeks 16, 24 and 32
Reported as:
Mean · Nanograms per milliliter
Ctrough of RPV LA (Q8W IM Dosing) Used for Assessment of Steady State (Maintenance Period)
Nanograms per milliliterCAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period)
Week 16, n=8741.94 ± 17.575
Week 24, n=8547.97 ± 22.341
Week 32, n=8357.24 ± 22.926
SecondaryCtrough of RPV LA (Q4W IM Dosing) Used for Assessment of Steady State (Maintenance Period)

Blood samples were collected at indicated time points for PK analysis of RPV LA. Ctrough is the lowest concentration reached by a drug before the next dose is administered. Ctrough for RPV LA (Q4W IM dosing) which were considered for the assessment of steady state are presented.

Time frame:
Pre-dose on Weeks 16, 20, 24, 28 and 32
Reported as:
Mean · Nanograms per milliliter
Ctrough of RPV LA (Q4W IM Dosing) Used for Assessment of Steady State (Maintenance Period)
Nanograms per milliliterCAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period)
Week 16, n=7866.92 ± 25.986
Week 20, n=7774.55 ± 29.156
Week 24, n=7876.84 ± 27.976
Week 28, n=8380.84 ± 31.297
Week 32, n=8590.34 ± 34.549
SecondaryPharmacodynamic Response (HIV-1 RNA<50 c/mL) in Relation With PK Parameter (AUC[0-tau]) of CAB LA and RPV LA at Week 32 (Maintenance Period)

Logistic regression was used to examine the correlation between pharmacodynamics response (HIV-1 RNA\<50 c/mL) at Week 32 and plasma PK parameter: area under plasma concentration-time curve from time zero to the end of dosing interval (AUC \[0-tau\]) of CAB LA and RPV LA per arm using MSDF (Missing, Switch or Discontinuation = Failure) algorithm. Estimates were obtained from logistic statistical model where the dependent variable is "HIV-1 RNA\<50 c/mL" (success) and the independent variable is PK parameter (AUC \[0-tau\]). Slopes and standard error are presented. Estimated effect represents the change in log odds for a one-unit increase in the PK parameter AUC (0-tau). Standard Error (SE)=0.000 is defined as following: if for all participants was resulted same value for the specific timepoint, then SE is equal with 0.000 .

Time frame:
Up to Week 32
Reported as:
Mean · Change in log odds
Pharmacodynamic Response (HIV-1 RNA<50 c/mL) in Relation With PK Parameter (AUC[0-tau]) of CAB LA and RPV LA at Week 32 (Maintenance Period)
Change in log oddsCAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period)CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period)CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period)
CAB LA0.00 ± 0.0010.00 ± 0.002—
RPV LA0.00 ± 0.0000.00 ± 0.000—
SecondaryPharmacodynamic Response (HIV-1 RNA<50 c/mL) in Relation With PK Parameter (Average C0) of CAB LA and RPV LA at Week 32 (Maintenance Period)

Logistic regression was used to examine the correlation between pharmacodynamics response (HIV-1 RNA\<50 c/mL) at Week 32 and plasma PK parameter: Average C0 of CAB LA and RPV LA per arm using MSDF (Missing, Switch or Discontinuation = Failure) algorithm. Estimates were obtained from logistic statistical model where the dependent variable is "HIV-1 RNA\<50 c/mL" (success) and the independent variable is PK parameter (Average C0). Slopes and standard error are presented. Estimated effect represents the change in log odds for a one-unit increase in the PK parameter Average C0.

Time frame:
Up to Week 32
Reported as:
Mean · Change in log odds
Pharmacodynamic Response (HIV-1 RNA<50 c/mL) in Relation With PK Parameter (Average C0) of CAB LA and RPV LA at Week 32 (Maintenance Period)
Change in log oddsCAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period)CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period)CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period)
CAB LA, n=100,108, 500.64 ± 0.8372.39 ± 1.9030.39 ± 0.528
RPV LA, n=101,104,490.00 ± 0.0250.01 ± 0.039-0.01 ± 0.020
SecondaryPharmacodynamic Response (HIV-1 RNA<50 c/mL) in Relation With PK Parameter (Cmax) of CAB LA and RPV LA at Week 32 (Maintenance Period)

Logistic regression was used to examine the correlation between pharmacodynamics response (HIV-1 RNA\<50 c/mL) at Week 32 and plasma PK parameter: Cmax of CAB LA and RPV LA per arm using MSDF (Missing, Switch or Discontinuation = Failure) algorithm. Estimates were obtained from logistic statistical model where the dependent variable is "HIV-1 RNA\<50 c/mL" (success) and the independent variable is PK parameter (Cmax). Slopes and standard error are presented. Estimated effect represents the change in log odds for a one-unit increase in the PK parameter Cmax.

Time frame:
Up to Week 32
Reported as:
Mean · Change in log odds
Pharmacodynamic Response (HIV-1 RNA<50 c/mL) in Relation With PK Parameter (Cmax) of CAB LA and RPV LA at Week 32 (Maintenance Period)
Change in log oddsCAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period)CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period)CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period)
CAB LA, n=98, 97,0-0.01 ± 0.1741.64 ± 1.707—
RPV LA, n=97,96,00.00 ± 0.0100.01 ± 0.027—
SecondaryVirologic Failure (From MSDF Algorithm) in Relation With PK Parameter (AUC[0-tau]) of CAB LA and RPV LA at Week 32 (Maintenance Period)

Logistic regression was used to examine the correlation between virologic failure at Week 32 and plasma PK parameter: AUC (0-tau) of CAB LA and RPV LA per arm using MSDF (Missing, Switch or Discontinuation = Failure) algorithm. Estimates were obtained from logistic statistical model where the dependent variable is "virologic failure" and the independent variable is PK parameter (AUC \[0-tau\]). Slopes and standard error are presented. Estimated effect represents the change in log odds for a one-unit increase in the PK parameter AUC (0-tau). SE=0.000 is defined as following: if for all participants was resulted same value for the specific timepoint, then SE is equal with 0.000.

Time frame:
Up to Week 32
Reported as:
Mean · Change in log odds
Virologic Failure (From MSDF Algorithm) in Relation With PK Parameter (AUC[0-tau]) of CAB LA and RPV LA at Week 32 (Maintenance Period)
Change in log oddsCAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period)CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period)CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period)
CAB LA-0.00 ± 0.001-0.00 ± 0.002—
RPV LA0.00 ± 0.000-0.00 ± 0.000—
SecondaryVirologic Failure (From MSDF Algorithm) in Relation With PK Parameter (Average C0) of CAB LA and RPV LA at Week 32 (Maintenance Period)

Logistic regression was used to examine the correlation between virologic failure at Week 32 and plasma PK parameter: Average C0 of CAB LA and RPV LA per arm using MSDF (Missing, Switch or Discontinuation = Failure) algorithm. Estimates were obtained from logistic statistical model where the dependent variable is "virologic failure" and the independent variable is PK parameter (Average C0). Slopes and standard error are presented. Estimated effect represents the change in log odds for a one-unit increase in the PK parameter Average C0.

Time frame:
Up to Week 32
Reported as:
Mean · Change in log odds
Virologic Failure (From MSDF Algorithm) in Relation With PK Parameter (Average C0) of CAB LA and RPV LA at Week 32 (Maintenance Period)
Change in log oddsCAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period)CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period)CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period)
CAB LA, n=100,108, 50-1.01 ± 1.014-2.39 ± 1.903-0.53 ± 0.796
RPV LA, n=101,104,49-0.00 ± 0.027-0.01 ± 0.039-0.01 ± 0.038
SecondaryVirologic Failure (From MSDF Algorithm) in Relation With PK Parameter (Cmax) of CAB LA and RPV LA at Week 32 (Maintenance Period)

Logistic regression was used to examine the correlation between virologic failure at Week 32 and plasma PK parameter: Cmax of CAB LA and RPV LA per arm using MSDF (Missing, Switch or Discontinuation = Failure) algorithm. Estimates were obtained from logistic statistical model where the dependent variable is "virologic failure" and the independent variable is PK parameter (Cmax). Slopes and standard error are presented. Estimated effect represents the change in log odds for a one-unit increase in the PK parameter Cmax.

Time frame:
Up to Week 32
Reported as:
Mean · Change in log odds
Virologic Failure (From MSDF Algorithm) in Relation With PK Parameter (Cmax) of CAB LA and RPV LA at Week 32 (Maintenance Period)
Change in log oddsCAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period)CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period)CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period)
CAB LA, n=98, 97,0-0.45 ± 0.509-1.64 ± 1.707—
RPV LA, n=97,96,0-0.00 ± 0.012-0.01 ± 0.027—
SecondaryNumber of Participants With Treatment-emergent Genotypic Resistance

Plasma samples were collected to assess treatment emergent Genotypic Resistance for participants who had confirmed virologic failure. Number of participants who had any Integrase Inhibitor (INI) mutations or major mutations of other classes (Nucleoside reverse transcriptase inhibitor \[NRTI\], Non-nucleoside reverse transcriptase inhibitor \[NNRTI\], protease inhibitor \[PI\])are presented.

Time frame:
Up to Week 32
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Genotypic Resistance
ParticipantsCAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period)CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period)CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period)
INI mutations0—0
Major mutations of other classes0—0
SecondaryNumber of Participants With Treatment-emergent Phenotypic Resistance

Plasma samples were collected for drug resistance testing. Number of participants, with treatment emergent phenotypic resistance to INI, NNRTI, NRTI and/or PI were summarized. Overall susceptibility of the drug was categorized as sensitive, partially sensitive and resistant.

Time frame:
Up to Week 32
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Phenotypic Resistance
ParticipantsCAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period)CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period)CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period)
INI, Sensitive1—1
INI, Partially sensitive0—0
INI, Resistant0—0
NNRTI, Sensitive1—1
NNRTI, Partially sensitive0—0
NNRTI, Resistant0—0
NRTI, Sensitive1—1
NRTI, Partially sensitive0—0
NRTI, Resistant0—0
PI, Sensitive1—1
PI, Partially sensitive0—0
PI, Resistant0—0
SecondaryPercentage of Participants With Plasma HIV-1 RNA Level <50 c/mL Over Week 32 by Subgroups (Maintenance Period)

Percentage of participants with HIV-1 RNA\<50 c/mL was obtained using FDA Snapshot algorithm. The algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as well as participants who switch their concomitant ART prior to the visit of interest, as non-responders. Data is presented for following subgroups: Baseline plasma HIV-1 RNA levels, Baseline CD4+ cell count, Race and HIV Risk factor (Homosexual contact \[HC\] and not injectable drug user).

Time frame:
Up to Week 32
Reported as:
Number · Percentage of participants
Percentage of Participants With Plasma HIV-1 RNA Level <50 c/mL Over Week 32 by Subgroups (Maintenance Period)
Percentage of participantsCAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period)CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period)CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period)
Baseline HIV-1 RNA<100000 c/mL, n=99,87,49969294
Baseline HIV-1 RNA>=100000 c/mL, n=16,28,78810071
Baseline HIV-1 RNA<1000 c/mL, n=0,3,1—100100
Baseline HIV-1 RNA 1000 to<10000c/mL, n=26,25,131008492
Baseline HIV-1 RNA 1000 to <50000c/mL, n=50,42,25493924
Baseline HIV-1 RNA 50000 to<100000c/mL,n=23,17,108710090
Baseline HIV-1 RNA>=100000 to<200000c/mL,n=9,13,28910050
Baseline plasma HIV-1 RNA >=200000 c/mL, n=7,15,58610080
Baseline CD4+ cell count <200 cells/mm^3, n=3,2,0100100—
Baseline CD4+ count 200 to<350cells/mm^3,n=30,23,89710088
Baseline CD4+ count >=350 cells/mm^3, n=82,90,48949292
Race-White, n=93,94,39959495
Race-Non-White, n=22,21,17959582
HC and not injectable drug user, n=98,90,40969490
No HC and not injectable drug user, n=17,25,16889294
SecondaryPercentage of Participants With Protocol Defined Virologic Failure (PDVF) at Week 32 by Subgroups(Maintenance Period)

Virologic failure was defined as any of the following: (1) Non-response as indicated by a less than a 1.0 log10 c/mL decrease in plasma HIV-1 RNA after 4 weeks of starting the Induction Period, which is subsequently confirmed, unless the plasma HIV-1 RNA is \< 400 c/mL; (2) Rebound as indicated by two consecutive plasma HIV-1 RNA levels \>=200 c/mL after prior suppression to \<200 c/mL; (3) Rebound as indicated by two consecutive plasma HIV-1 RNA that are \> 0.5 log10 c/mL increase in plasma HIV-1 RNA from the nadir value on study, where the lowest HIV-1 RNA value is \>=200 c/mL. Data is presented for following subgroups: Baseline plasma HIV-1 RNA levels, Baseline CD4+ cell count, Race and HIV Risk factor (Homosexual contact \[HC\] and not injectable drug user).

Time frame:
Up to Week 32
Reported as:
Number · Percentage of participants
Percentage of Participants With Protocol Defined Virologic Failure (PDVF) at Week 32 by Subgroups(Maintenance Period)
Percentage of participantsCAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period)CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period)CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period)
Baseline HIV-1 RNA<100000 c/mL, n=99,87,49310
Baseline HIV-1 RNA>=100000 c/mL, n=16,28,713029
Baseline HIV-1 RNA<1000 c/mL, n=0,3,1—00
Baseline HIV-1 RNA 1000 to<10000c/mL, n=26,25,13040
Baseline HIV-1 RNA 1000 to <50000c/mL, n=50,42,25200
Baseline HIV-1 RNA 50000 to<100000c/mL,n=23,17,10900
Baseline HIV-1 RNA>=100000 to<200000c/mL,n=9,13,211050
Baseline plasma HIV-1 RNA >=200000 c/mL, n=7,15,514020
Baseline CD4+ cell count <200 cells/mm^3, n=3,2,000—
Baseline CD4+ count 200 to<350cells/mm^3,n=30,23,80013
Baseline CD4+ count >=350 cells/mm^3, n=82,90,48612
Race-White, n=93,94,39410
Race-Non-White, n=22,21,175012
HC and not injectable drug user, n=98,90,40315
No HC and not injectable drug user, n=17,25,161200
SecondaryHIV Treatment Satisfaction Questionnaire - Status Version (HIVTSQ[s]) Total Score at Week 32 and Week 96 (Maintenance Period)

The HIVTSQ(s) was developed to evaluate treatments for HIV and participant satisfaction. It has total 14 items and each items are scored from 6 (very satisfied) to 0 (very dissatisfied). Items 1 to 12 are summed to produce the Total Treatment Satisfaction Score with a possible range of 0 to 72. Higher scores represent greater treatment satisfaction as compared to the past few weeks.

Time frame:
At Week 32 and Week 96
Reported as:
Mean · Scores on a scale
HIV Treatment Satisfaction Questionnaire - Status Version (HIVTSQ[s]) Total Score at Week 32 and Week 96 (Maintenance Period)
Scores on a scaleCAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period)CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period)CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period)
Week 3268.4 ± 4.4866.6 ± 6.4765.1 ± 5.83
Week 9668.4 ± 4.3467.0 ± 5.2063.5 ± 9.75
SecondaryHIV Treatment Satisfaction Questionnaire - Change Version (HIVTSQ[c]) Total Score at Week 32 (Maintenance Period)

The HIVTSQ(c) was developed to evaluate treatments for HIV and participant satisfaction. It has total 14 items and each items are scored from +3 ('much more satisfied', 'much more convenient', 'much more flexible', etc.) to -3 ('much less satisfied', 'much less convenient', 'much less flexible', etc.). Items 1 to 12 (excluding Items 7b and 9b) are summed to produce a Total Treatment Satisfaction Score (change) with a possible range of -33 to +33. The higher the score, the greater the improvement in satisfaction with treatment; the lower the score, the greater the deterioration in satisfaction with treatment.

Time frame:
Week 32
Reported as:
Mean · Scores on a scale
HIV Treatment Satisfaction Questionnaire - Change Version (HIVTSQ[c]) Total Score at Week 32 (Maintenance Period)
Scores on a scaleCAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period)CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period)CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period)
HIV Treatment Satisfaction Questionnaire - Change Version (HIVTSQ[c]) Total Score at Week 32 (Maintenance Period)30.9 ± 7.5628.9 ± 8.5320.5 ± 14.09
SecondaryNumber of Participants With HIV Medication Questionnaire (HIVMQ) Item E and F Scores at Week 32 (Maintenance Period)

The HIVMQ was developed to assess participant reported medication adherence. It has 6 items (a, b, c, d, e, f). Item E (How often do you find it inconvenient or difficult to take/receive medication as recommended?) and Item F (How much pain/discomfort have experienced with this medication?). Each of these 2 items are scored from 0 (none of the time) to 6 (all of the time). The higher the score, the greater the adherence to medication. Number of participants with HIVMQ Item E and F Scores at Week 32 by their score categories (0: none of the time to 6: all of the time) are presented.

Time frame:
Week 32
Reported as:
Count of participants · Participants
Number of Participants With HIV Medication Questionnaire (HIVMQ) Item E and F Scores at Week 32 (Maintenance Period)
ParticipantsCAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period)CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period)CAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period)
Item E, score 0807316
Item E, score 1121413
Item E, score 2322
Item E, score 3263
Item E, score 4011
Item E, score 52412
Item E, score 61063
Item F, Score 0403329
Item F, Score 1354312
Item F, Score 217162
Item F, Score 3652
Item F, Score 4733
Item F, Score 5440
Item F, Score 6022
SecondaryNumber of Participants With HIV Medication Questionnaire (HIVMQ) Item E and F Scores at Week 96 (Maintenance Period)

The HIVMQ was developed to assess participant reported medication adherence. It has 6 items (a, b, c, d, e, f). Item E (How often do you find it inconvenient or difficult to take/receive medication as recommended?) and Item F (How much pain/discomfort have experienced with this medication?). Each of these 2 items are scored from 0 (none of the time) to 6 (all of the time). The higher the score, the greater the adherence to medication. Number of participants with HIVMQ Item E and F Scores at Week 96 by their score categories (0: none of the time to 6: all of the time) are presented.

Time frame:
Week 96
Reported as:
Count of participants · Participants
Number of Participants With HIV Medication Questionnaire (HIVMQ) Item E and F Scores at Week 96 (Maintenance Period)
ParticipantsCAB 30 mg+ABC/3TC QD (Induction Period and Maintenance Period)
Item E, score 018
Item E, score 110
Item E, score 23
Item E, score 32
Item E, score 41
Item E, score 59
Item E, score 63
Item F, Score 03
Item F, Score 18
Item F, Score 24
Item F, Score 31
Item F, Score 40
Item F, Score 51
Item F, Score 61

Adverse events

Collected over All-cause mortality, SAEs and non-SAEs were collected from start of the study treatment up to end of Extension and LTFU Periods (up to approximately 468 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CAB 30 mg+ABC/3TC QD (Induction Period)1/309 (0.3%)8/309 (2.6%)145/309 (46.9%)
CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period)0/115 (0%)31/115 (27%)115/115 (100%)
CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period)3/115 (2.6%)31/115 (27%)115/115 (100%)
CAB 30 mg+ABC/3TC QD0/56 (0%)9/56 (16.1%)52/56 (92.9%)
Optimized CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Extension Period)0/34 (0%)9/34 (26.5%)34/34 (100%)
Optimized CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Extension Period)0/10 (0%)1/10 (10%)10/10 (100%)
Long-Term Follow-Up Group0/43 (0%)7/43 (16.3%)7/43 (16.3%)
Most frequent serious events
Showing 10 of 144
Most frequent serious events
EventCAB 30 mg+ABC/3TC QD (Induction Period)CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period)CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period)CAB 30 mg+ABC/3TC QDOptimized CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Extension Period)Optimized CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Extension Period)Long-Term Follow-Up Group
VIth nerve paralysisNervous system disorders0/3090/1150/1150/560/341/100/43
PneumoniaInfections and infestations0/3090/1150/1150/562/340/100/43
Suicide attemptPsychiatric disorders0/3092/1151/1150/560/340/102/43
Road traffic accidentInjury, poisoning and procedural complications1/3090/1150/1150/561/340/100/43
Abdominal painGastrointestinal disorders0/3090/1151/1150/561/340/100/43
COVID-19 pneumoniaInfections and infestations0/3090/1150/1150/561/340/100/43
Gastroenteritis viralInfections and infestations0/3090/1150/1150/561/340/100/43
Meningitis asepticInfections and infestations0/3090/1150/1150/561/340/100/43
Abdominal pain upperGastrointestinal disorders0/3090/1150/1150/561/340/100/43
Tendon ruptureInjury, poisoning and procedural complications0/3090/1150/1150/561/340/100/43
Most frequent other events
Showing 10 of 96
Most frequent other events
EventCAB 30 mg+ABC/3TC QD (Induction Period)CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Maintenance and Extension Period)CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Maintenance and Extension Period)CAB 30 mg+ABC/3TC QDOptimized CAB LA 600 mg+RPV LA 900 mg IM-Q8W (Extension Period)Optimized CAB LA 400 mg+RPV LA 600 mg IM-Q4W (Extension Period)Long-Term Follow-Up Group
Injection site painGeneral disorders0/309111/115114/1150/5631/348/104/43
Injection site noduleGeneral disorders0/30946/11557/1150/5612/345/100/43
NasopharyngitisInfections and infestations27/30954/11554/11522/568/345/100/43
Injection site swellingGeneral disorders0/30941/11543/1150/566/343/100/43
Injection site pruritusGeneral disorders0/30940/11540/1150/564/342/100/43
DiarrhoeaGastrointestinal disorders34/30939/11535/11511/564/343/100/43
SyphilisInfections and infestations0/30936/11528/1156/564/343/100/43
InfluenzaInfections and infestations0/30921/11532/1150/567/343/100/43
Back painMusculoskeletal and connective tissue disorders0/30927/11530/11510/568/343/100/43
ArthralgiaMusculoskeletal and connective tissue disorders0/30927/11521/1154/566/343/100/43

Baseline characteristics

309 participants are valid only for the Induction Phase of the study (Weeks -20 to Day 1). Participants (n=286) were randomized at Day 1 of the Maintenance Phase.

Age, Continuous
Age, Continuous(Years)CAB 30 mg+ABC/3TC QD
Mean36.6 ± 10.39
Sex: Female, Male
Sex: Female, Male(Participants)CAB 30 mg+ABC/3TC QD
Female27
Male282
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)CAB 30 mg+ABC/3TC QD
Race — African American/African Heritage46
Race — American Indian or Alaskan Native10
Race — Asian - Central/South Asian Heritage1
Race — Asian - Japanese Heritage1
Race — Asian - South East Asian Heritage2
Race — Native Hawaiian or Other Pacific Islander1
Race — White - Arabic/North African Heritage6
Race — White - White/Caucasian/European Heritage240
Race — Mixed Race2
09

Study locations

50 sites
  • GSK Investigational Site
    Birmingham, Alabama 35294, United States
  • GSK Investigational Site
    Bakersfield, California 93301, United States
  • GSK Investigational Site
    Beverly Hills, California 90211, United States
  • GSK Investigational Site
    Long Beach, California 90813, United States
  • GSK Investigational Site
    Los Angeles, California 90069, United States
  • GSK Investigational Site
    Denver, Colorado 80246, United States
  • GSK Investigational Site
    Fort Lauderdale, Florida 33316, United States
  • GSK Investigational Site
    Fort Pierce, Florida 34982, United States
  • GSK Investigational Site
    Savannah, Georgia 31401, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55415, United States
  • GSK Investigational Site
    Omaha, Nebraska 68198, United States
  • GSK Investigational Site
    Chapel Hill, North Carolina 27514, United States
  • GSK Investigational Site
    Providence, Rhode Island 02904, United States
  • GSK Investigational Site
    Austin, Texas 78705, United States
  • GSK Investigational Site
    Dallas, Texas 75246, United States
  • GSK Investigational Site
    Vancouver, British Columbia V6Z 2C7, Canada
  • GSK Investigational Site
    Winnipeg, Manitoba R3A 1R9, Canada
  • GSK Investigational Site
    Ottawa, Ontario K1H 8L6, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 1K2, Canada
  • GSK Investigational Site
    Montreal, Quebec H2L 4E9, Canada
  • GSK Investigational Site
    Montreal, Quebec H2L 4P9, Canada
  • GSK Investigational Site
    Montreal, Quebec H3A 1T1, Canada
  • GSK Investigational Site
    Montreal, Quebec H4A 3J1, Canada
  • GSK Investigational Site
    Bobigny, 93009, France
  • GSK Investigational Site
    Lyon Cedex 03, 69437, France
  • GSK Investigational Site
    Marseille, 13274, France
  • GSK Investigational Site
    Nantes, 44093, France
  • GSK Investigational Site
    Nice, 06202, France
  • GSK Investigational Site
    Paris Cedex 12, 75571, France
  • GSK Investigational Site
    Paris Cedex 20, 75970, France
  • GSK Investigational Site
    Paris, 75018, France
  • GSK Investigational Site
    Saint Denis Cedex 01, 93205, France
  • GSK Investigational Site
    Muenchen, Bayern 80337, Germany
  • GSK Investigational Site
    Frankfurt, Hessen 60596, Germany
  • GSK Investigational Site
    Hannover, Niedersachsen 30625, Germany
  • GSK Investigational Site
    Bonn, Nordrhein-Westfalen 53127, Germany
  • GSK Investigational Site
    Berlin, 10439, Germany
  • GSK Investigational Site
    Berlin, 10787, Germany
  • GSK Investigational Site
    Berlin, 13353, Germany
  • GSK Investigational Site
    Hamburg, 20146, Germany
  • GSK Investigational Site
    Hamburg, 20246, Germany
  • GSK Investigational Site
    Badalona, 08916, Spain
  • GSK Investigational Site
    Barcelona, 08025, Spain
  • GSK Investigational Site
    Barcelona, 08036, Spain
  • GSK Investigational Site
    Barcelona, 08907, Spain
  • GSK Investigational Site
    Elche, ?03203, Spain
  • GSK Investigational Site
    Madrid, 28007, Spain
  • GSK Investigational Site
    Madrid, 28040, Spain
  • GSK Investigational Site
    Madrid, 28041, Spain
  • GSK Investigational Site
    Madrid, 28046, Spain
10

References and documents

Publications

  • Kerrigan D, Mantsios A, Gorgolas M, Montes ML, Pulido F, Brinson C, deVente J, Richmond GJ, Beckham SW, Hammond P, Margolis D, Murray M. Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain. PLoS One. 2018 Jan 5;13(1):e0190487. doi: 10.1371/journal.pone.0190487. eCollection 2018. PubMed 29304154 ↗
  • Smith GHR, Henry WK, Podzamczer D, Masia MDM, Bettacchi CJ, Arasteh K, Jaeger H, Khuong-Josses MA, Montes-Ramirez ML, Stellbrink HJ, Yazdanpanah Y, Richmond GJ, Sutton KC, Zhang F, McCoig CC, St Clair MH, Vandermeulen K, Van Solingen-Ristea R, Smith KY, Margolis DA, Spreen WR. Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study. Open Forum Infect Dis. 2021 Aug 25;8(9):ofab439. doi: 10.1093/ofid/ofab439. eCollection 2021 Sep. PubMed 34557563 ↗
  • Letendre SL, Mills A, Hagins D, Swindells S, Felizarta F, Devente J, Bettacchi C, Lou Y, Ford S, Sutton K, Shaik JS, Crauwels H, D'Amico R, Patel P. Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults. J Antimicrob Chemother. 2020 Mar 1;75(3):648-655. doi: 10.1093/jac/dkz504. PubMed 31873746 ↗
  • Murray M, Pulido F, Mills A, Ramgopal M, LeBlanc R, Jaeger H, Canon V, Dorey D, Griffith S, Mrus J, Spreen W, Margolis D. Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study. HIV Res Clin Pract. 2019 Aug-Oct;20(4-5):111-122. doi: 10.1080/25787489.2019.1661696. Epub 2019 Sep 18. PubMed 31533539 ↗
  • Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, Eron JJ, Yazdanpanah Y, Podzamczer D, Lutz T, Angel JB, Richmond GJ, Clotet B, Gutierrez F, Sloan L, Clair MS, Murray M, Ford SL, Mrus J, Patel P, Crauwels H, Griffith SK, Sutton KC, Dorey D, Smith KY, Williams PE, Spreen WR. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet. 2017 Sep 23;390(10101):1499-1510. doi: 10.1016/S0140-6736(17)31917-7. Epub 2017 Jul 24. PubMed 28750935 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2014 to primary completion in Aug 2015, 15 months.

Results were first posted in Aug 2020, 5 years after primary completion. A results delay was requested in Dec 2015.

Of 34 industry-sponsored phase 2 interventional studies under HIV Infections, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's 15 months is below that.

Counting every sponsor, half of 99 studies reached it within 31 months; a quarter within 17 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2014
First posted
Apr 22, 2014
StartActual
Apr 28, 2014
Primary completionActual
Aug 13, 2015
CompletionActual
Apr 20, 2023
Results delay requested
Dec 10, 2015
Results first posted
Aug 31, 2020
Last update
Jun 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02120352
Lead sponsor
ViiV Healthcare
Responsible party
Sponsor
First posted
Apr 22, 2014
Start date
Apr 28, 2014
Primary completion
Aug 13, 2015
Completion
Apr 20, 2023
Results posted
Aug 31, 2020
Last update
Jun 12, 2024

Study contacts

GSK Clinical Trials
study director · ViiV Healthcare

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cabotegravir

Start the discussion